![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Novartis Ag Basel Namen Akt (PK) | USOTC:NVSEF | OTCMarkets | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 105.17 | 104.29 | 118.12 | 20 | 21:20:00 |
Form 20-F: x
|
Form 40-F: o
|
Yes: o
|
No: x
|
Yes: o
|
No: x
|
Yes: o
|
No: x
|
Novartis AG
|
|||
Date:
January 27, 2016
|
By:
|
/s/ PAUL PENEPENT
|
|
Name:
|
Paul Penepent
|
||
Title:
|
Head Group Financial Reporting and Accounting
|
||
![]() |
Novartis International AG
Novartis Global Communications
CH-4002 Basel
Switzerland
http://www.novartis.com
http://www.novartis.com
|
·
|
Strong growth (cc) in full year sales, core operating income and core EPS2
|
o
|
Net sales up 5% (cc) and core operating income up 10% (cc)
|
o
|
Core operating income margin up 1.3 percentage points (cc)
|
o
|
Operating income (-2% cc) down mainly due to amortization of the new oncology assets
|
o
|
Net income (-18% cc) impacted by exceptional gains in 2014 (from the sale of shares in Idenix and LTS) and exceptional charges in 2015 (related to Venezuela subsidiaries)
|
o
|
Core EPS up 10% (cc) to USD 5.01
|
o
|
Currency negatively impacted sales by -10% and core operating income by -15%
|
o
|
Free cash flow of USD 9.3 billion, down 15% (USD) due to currency
|
·
|
Solid Q4 with net sales up 4% (cc) and core operating income up 9% (cc)
|
o
|
Strong Pharmaceuticals performance offset weak Alcon
|
·
|
Innovation momentum continued with key approvals and filings in Q4
|
o
|
Entresto approved for chronic heart failure in EU
|
o
|
Cosentyx approved for AS and PsA in EU and, in January 2016, in US
|
o
|
Sandoz submitted biosimilar etanercept in EU and pegfilgrastim in US
|
·
|
Focusing Alcon Division on core Surgical and Vision Care business, with growth plan underway
|
o
|
Alcon ophthalmic pharmaceuticals business to move to Pharmaceuticals Division, combining Alcon’s strong brand with Pharmaceuticals strengths in development and marketing
|
·
|
Leveraging Group scale to drive even greater efficiency and innovation
|
o
|
Centralizing manufacturing operations across Group to optimize capacity planning and lower costs
|
o
|
Integrating some drug development functions across divisions to improve resource allocation, technology and standards to increase innovation even further
|
o
|
Changes expected to generate over USD 1 billion in annual cost savings by 2020, ramp-up starting in 2016; one-time restructuring costs of approximately USD 1.4 billion spread over 5 years
|
·
|
Novartis leadership changes effective February 1, 2016
|
o
|
Mike Ball appointed Division Head and CEO Alcon, succeeding Jeff George
|
o
|
Vas Narasimhan appointed Global Head Drug Development and Chief Medical Officer
|
o
|
Andre Wyss appointed President Novartis Operations
|
·
|
Dividend of CHF 2.70 per share, up 4%, proposed for 2015
|
·
|
2016 Outlook2
|
o
|
Net sales and core operating income expected to be broadly in line with prior year (cc)
|
Key figures1
|
Continuing operations2
|
|||||||||||||||||||||||||||||||
Q4 2015
|
Q4 2014
|
% change
|
FY 2015
|
FY 2014
|
% change
|
|||||||||||||||||||||||||||
|
USD m
|
USD m
|
USD
|
cc
|
USD m
|
USD m
|
USD
|
cc
|
||||||||||||||||||||||||
Net sales
|
12 520
|
13 075
|
-4
|
4
|
49 414
|
52 180
|
-5
|
5
|
||||||||||||||||||||||||
Operating income
|
1 677
|
2 351
|
-29
|
-12
|
8 977
|
11 089
|
-19
|
-2
|
||||||||||||||||||||||||
Net income
|
1 054
|
2 448
|
-57
|
-34
|
7 028
|
10 727
|
-34
|
-18
|
||||||||||||||||||||||||
EPS (USD)
|
0.44
|
1.02
|
-57
|
-34
|
2.92
|
4.39
|
-33
|
-17
|
||||||||||||||||||||||||
Free cash flow
|
2 942
|
3 955
|
-26
|
9 259
|
10 934
|
-15
|
||||||||||||||||||||||||||
Core
|
||||||||||||||||||||||||||||||||
Operating income
|
3 057
|
3 229
|
-5
|
9
|
13 790
|
14 473
|
-5
|
10
|
||||||||||||||||||||||||
Net income
|
2 707
|
2 857
|
-5
|
7
|
12 041
|
12 653
|
-5
|
9
|
||||||||||||||||||||||||
EPS (USD)
|
1.14
|
1.19
|
-4
|
8
|
5.01
|
5.19
|
-3
|
10
|
·
|
Optimizing IOL innovation and commercial execution
|
·
|
Prioritizing and investing in promising pipeline opportunities
|
·
|
Ensuring best-in-class service, training and education for eye care professionals
|
·
|
Improving sales force effectiveness
|
·
|
Investing in DTC behind key brands
|
·
|
Mike Ball, Division Head and CEO Alcon
|
·
|
Vas Narasimhan, Global Head Drug Development and Chief Medical Officer
|
·
|
Andre Wyss, President Novartis Operations
|
·
|
Growth Products, an indicator of the ongoing rejuvenation of our portfolio, contributed 35% of continuing operations net sales in the fourth quarter, and were up 16% (USD). In Pharmaceuticals, Growth Products contributed 47% of division net sales in the quarter, and sales for these products were up 34% (cc).
|
·
|
Gilenya (USD 742 million, +18% cc), our oral MS therapy, grew double-digit in the quarter behind strong volume growth.
|
·
|
Tasigna (USD 432 million, +8% cc) continued to drive growth in our CML franchise (which also includes Gleevec/Glivec), with strong volume growth in the US and other markets.
|
·
|
Tafinlar + Mekinist (USD 147 million) grew as the first approved combination therapy for the treatment of patients with BRAF V600 mutation positive unresectable or metastatic melanoma.
|
·
|
Promacta/Revolade (USD 133 million) saw sales accelerate as the only approved once-daily oral thrombopoietin receptor agonist.
|
·
|
Jakavi (USD 119 million, +59% cc), an oral JAK inhibitor approved for myelofibrosis and polycythemia vera, grew strongly over the previous-year quarter.
|
·
|
Cosentyx (USD 121 million), the first IL-17A inhibitor approved in the US and Europe for psoriasis patients (and as of the fourth quarter, for ankylosing spondylitis and psoriatic arthritis patients in Europe as well), has progressed strongly since its launch in February 2015.
|
·
|
Entresto (USD 5 million), our breakthrough treatment for chronic heart failure with reduced ejection fraction, had modest sales in the fourth quarter due to continuing NDC blocks.
|
·
|
Biopharmaceuticals (which include biosimilars, biopharmaceutical contract manufacturing and Glatopa) grew 41% (cc) to USD 218 million.
|
·
|
Continuing operations net sales in our Emerging Growth Markets – which comprise all markets except the US, Canada, Western Europe, Japan, Australia and New Zealand – grew 4% (cc) in the fourth quarter, reflecting a general slowdown in the Chinese economy. Growth was led by Turkey (+16% cc) and Brazil (+14% cc). China grew 5% (cc).
|
·
|
Entresto approved in EU
|
·
|
Cosentyx approved for AS and PsA in EU, and in US in January
|
·
|
FDA approved Utibron Neohaler for COPD
|
·
|
Tafinlar + Mekinist received regular approval in US
|
·
|
FDA granted Afinitor priority review in GI/lung NET
|
·
|
Sandoz submitted biosimilar etanercept in Europe
|
·
|
Sandoz submitted biosimilar pegfilgrastim in the US
|
·
|
Two year Phase III data for Cosentyx showed sustained efficacy in AS and PsA
|
·
|
Phase III studies for Cosentyx in AS published in NEJM
|
·
|
RELAX-AHF-2 study of serelaxin continued following interim analysis
|
·
|
Novartis continued to grow immuno-oncology pipeline through collaboration and licensing agreement with Surface Oncology
|
·
|
New CTL019 data in relapsed/refractory ALL presented at ASH
|
·
|
Five year Phase III Jakavi data reinforced long-term treatment benefit in MF
|
·
|
Ultibro Breezhaler demonstrated superiority over Seretide® in COPD
|
·
|
Phase III PKC412 data showed survival benefit in certain AML patients
|
·
|
Promacta/Revolade studies in MDS/AML discontinued
|
·
|
Alcon launched Contoura Vision as first personalized LASIK procedure
|
·
|
Novartis Business Services (NBS), our cross-divisional services organization, continued to execute on its priorities of driving efficiency, standardization and simplification across the Group. The organization continued to scale up the offshoring of transactional services to Global Service Centers, and at the end of the fourth quarter, had approximately 9,500 full-time-equivalent associates, transferred from within the Novartis Group. The cost within the scope of NBS was stable from the prior year, contributing to Group margin improvement.
|
·
|
In the fourth quarter, we generated approximately USD 480 million in procurement savings, in part by leveraging our scale through NBS.
|
·
|
In addition, we continued to streamline our manufacturing footprint. In the fourth quarter, we finalized the divestment of our Alcon manufacturing site in Kaysersberg, France to Recipharm. For continuing operations, this brings the total number of production sites that have been or are in the process of being restructured, closed or divested to 25. Exceptional charges were USD 76 million in the fourth quarter and USD 375 million in the full year. Exceptional charges recorded cumulatively since the program began amount to USD 950 million.
|
·
|
Pharmaceuticals: broadly in line with 2015 to a slight decline (mid-single digit growth excluding Glivec generic impact)
|
·
|
Alcon: low single digit growth
|
·
|
Sandoz: low to mid-single digit growth
|
Continuing operations1
|
Q4 2015
|
Q4 2014
|
% change
|
FY 2015
|
FY 2014
|
% change
|
||||||||||||||||||||||||||
|
USD m
|
USD m
|
USD
|
cc
|
USD m
|
USD m
|
USD
|
cc
|
||||||||||||||||||||||||
Net sales
|
12 520
|
13 075
|
-4
|
4
|
49 414
|
52 180
|
-5
|
5
|
||||||||||||||||||||||||
Operating income
|
1 677
|
2 351
|
-29
|
-12
|
8 977
|
11 089
|
-19
|
-2
|
||||||||||||||||||||||||
As a % of sales
|
13.4
|
18.0
|
18.2
|
21.3
|
||||||||||||||||||||||||||||
Core operating income
|
3 057
|
3 229
|
-5
|
9
|
13 790
|
14 473
|
-5
|
10
|
||||||||||||||||||||||||
As a % of sales
|
24.4
|
24.7
|
27.9
|
27.7
|
||||||||||||||||||||||||||||
Pharmaceuticals
|
Q4 2015
|
Q4 2014
|
% change
|
FY 2015
|
FY 2014
|
% change
|
||||||||||||||||||||||||||
|
USD m
|
USD m
|
USD
|
cc
|
USD m
|
USD m
|
USD
|
cc
|
||||||||||||||||||||||||
Net sales
|
7 865
|
7 860
|
0
|
9
|
30 445
|
31 791
|
-4
|
6
|
||||||||||||||||||||||||
Operating income
|
1 471
|
1 611
|
-9
|
9
|
7 597
|
8 471
|
-10
|
5
|
||||||||||||||||||||||||
As a % of sales
|
18.7
|
20.5
|
25.0
|
26.6
|
||||||||||||||||||||||||||||
Core operating income
|
2 105
|
1 977
|
6
|
23
|
9 420
|
9 514
|
-1
|
14
|
||||||||||||||||||||||||
As a % of sales
|
26.8
|
25.2
|
30.9
|
29.9
|
||||||||||||||||||||||||||||
Alcon
|
Q4 2015
|
Q4 2014
|
% change
|
FY 2015
|
FY 2014
|
% change
|
||||||||||||||||||||||||||
USD m
|
USD m
|
USD
|
cc
|
USD m
|
USD m
|
USD
|
cc
|
|||||||||||||||||||||||||
Net sales
|
2 349
|
2 703
|
-13
|
-6
|
9 812
|
10 827
|
-9
|
-1
|
||||||||||||||||||||||||
Operating income
|
132
|
365
|
-64
|
-36
|
794
|
1 597
|
-50
|
-20
|
||||||||||||||||||||||||
As a % of sales
|
5.6
|
13.5
|
8.1
|
14.8
|
||||||||||||||||||||||||||||
Core operating income
|
670
|
895
|
-25
|
-13
|
3 063
|
3 811
|
-20
|
-7
|
||||||||||||||||||||||||
As a % of sales
|
28.5
|
33.1
|
31.2
|
35.2
|
||||||||||||||||||||||||||||
Sandoz
|
Q4 2015
|
Q4 2014
|
% change
|
FY 2015
|
FY 2014
|
% change
|
||||||||||||||||||||||||||
|
USD m
|
USD m
|
USD
|
cc
|
USD m
|
USD m
|
USD
|
cc
|
||||||||||||||||||||||||
Net sales
|
2 306
|
2 512
|
-8
|
0
|
9 157
|
9 562
|
-4
|
7
|
||||||||||||||||||||||||
Operating income
|
216
|
290
|
-26
|
-18
|
1 005
|
1 088
|
-8
|
1
|
||||||||||||||||||||||||
As a % of sales
|
9.4
|
11.5
|
11.0
|
11.4
|
||||||||||||||||||||||||||||
Core operating income
|
397
|
416
|
-5
|
4
|
1 659
|
1 571
|
6
|
17
|
||||||||||||||||||||||||
As a % of sales
|
17.2
|
16.6
|
18.1
|
16.4
|
||||||||||||||||||||||||||||
Corporate
|
Q4 2015
|
Q4 2014
|
% change
|
FY 2015
|
FY 2014
|
% change
|
||||||||||||||||||||||||||
|
USD m
|
USD m
|
USD
|
cc
|
USD m
|
USD m
|
USD
|
cc
|
||||||||||||||||||||||||
Operating loss
|
-142
|
85
|
nm
|
nm
|
-419
|
-67
|
nm
|
nm
|
||||||||||||||||||||||||
Core operating loss
|
-115
|
-59
|
-95
|
-113
|
-352
|
-423
|
17
|
11
|
||||||||||||||||||||||||
Discontinued operations
|
Q4 2015
|
Q4 2014
|
% change
|
FY 2015
|
FY 2014
|
% change
|
||||||||||||||||||||||||||
|
USD m
|
USD m
|
USD
|
cc
|
USD m
|
USD m
|
USD
|
cc
|
||||||||||||||||||||||||
Net sales
|
0
|
1 558
|
nm
|
nm
|
601
|
5 816
|
nm
|
nm
|
||||||||||||||||||||||||
Operating income
|
-94
|
-1 179
|
nm
|
nm
|
12 477
|
-353
|
nm
|
nm
|
||||||||||||||||||||||||
As a % of sales
|
nm
|
-75.7
|
nm
|
-6.1
|
||||||||||||||||||||||||||||
Core operating loss/income
|
-2
|
93
|
nm
|
nm
|
-225
|
143
|
nm
|
nm
|
||||||||||||||||||||||||
As a % of sales
|
nm
|
6.0
|
-37.4
|
2.5
|
||||||||||||||||||||||||||||
Total Group2
|
Q4 2015
|
Q4 2014
|
% change
|
FY 2015
|
FY 2014
|
% change
|
||||||||||||||||||||||||||
|
USD m
|
USD m
|
USD
|
cc
|
USD m
|
USD m
|
USD
|
cc
|
||||||||||||||||||||||||
Net income
|
1 056
|
1 487
|
-29
|
12
|
17 794
|
10 280
|
73
|
91
|
||||||||||||||||||||||||
EPS (USD)
|
0.44
|
0.62
|
-29
|
12
|
7.40
|
4.21
|
76
|
94
|
||||||||||||||||||||||||
Free cash flow
|
3 002
|
4 419
|
-32
|
9 029
|
10 762
|
-16
|
INDEX
|
Page
|
GROUP AND DIVISIONAL OPERATING PERFORMANCE Q4 AND FY 2015
|
|
Group
|
2
|
Pharmaceuticals
|
6
|
Alcon
|
15
|
Sandoz
|
18
|
Discontinued operations
|
20
|
CASH FLOW AND GROUP BALANCE SHEET
|
22
|
INNOVATION REVIEW
|
25
|
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
|
|
Condensed consolidated income statements
|
33
|
Condensed consolidated statements of comprehensive income
|
35
|
Condensed consolidated balance sheets
|
36
|
Condensed consolidated changes in equity
|
37
|
Condensed consolidated cash flow statements
|
38
|
Notes to condensed consolidated financial statements, including update on legal proceedings
|
40
|
SUPPLEMENTARY INFORMATION
|
53
|
CORE RESULTS
|
|
Reconciliation from IFRS to core results
|
55
|
Group
|
57
|
Pharmaceuticals
|
59
|
Alcon
|
61
|
Sandoz
|
63
|
Corporate
|
65
|
Discontinued operations
|
67
|
ADDITIONAL INFORMATION
|
|
Condensed consolidated changes in net debt / Share information
|
69
|
Free cash flow
|
70
|
Net sales of the top 20 Pharmaceuticals products
|
71
|
Pharmaceuticals sales by business franchise
|
73
|
Net sales by region
|
75
|
Currency translation rates
|
77
|
Income from associated companies
|
78
|
DISCLAIMER
|
79
|
![]() |
Novartis International AG
Novartis Global Communications
CH-4002 Basel
Switzerland
http://www.novartis.com
http://www.novartis.com
|
INDEX
|
Page
|
GROUP AND DIVISIONAL OPERATING PERFORMANCE Q4 AND FY 2015
|
|
Group
|
2
|
Pharmaceuticals
|
6
|
Alcon
|
15
|
Sandoz
|
18
|
Discontinued operations
|
20
|
CASH FLOW AND GROUP BALANCE SHEET
|
22
|
INNOVATION REVIEW
|
25
|
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
|
|
Condensed consolidated income statements
|
33
|
Condensed consolidated statements of comprehensive income
|
35
|
Condensed consolidated balance sheets
|
36
|
Condensed consolidated changes in equity
|
37
|
Condensed consolidated cash flow statements
|
38
|
Notes to condensed consolidated financial statements, including update on legal proceedings
|
40
|
SUPPLEMENTARY INFORMATION
|
53
|
CORE RESULTS
|
|
Reconciliation from IFRS to core results
|
55
|
Group
|
57
|
Pharmaceuticals
|
59
|
Alcon
|
61
|
Sandoz
|
63
|
Corporate
|
65
|
Discontinued operations
|
67
|
ADDITIONAL INFORMATION
|
|
Condensed consolidated changes in net debt / Share information
|
69
|
Free cash flow
|
70
|
Net sales of the top 20 Pharmaceuticals products
|
71
|
Pharmaceuticals sales by business franchise
|
73
|
Net sales by region
|
75
|
Currency translation rates
|
77
|
Income from associated companies
|
78
|
DISCLAIMER
|
79
|
Key figures1
|
Q4 2015
|
Q4 2014
|
% change
|
FY 2015
|
FY 2014
|
% change
|
||||||||||||||||||||||||||
|
USD m
|
USD m
|
USD
|
cc2
|
USD m
|
USD m
|
USD
|
cc2
|
||||||||||||||||||||||||
Net sales to third parties from continuing operations
|
12 520
|
13 075
|
-4
|
4
|
49 414
|
52 180
|
-5
|
5
|
||||||||||||||||||||||||
Divisional operating income from continuing operations
|
1 819
|
2 266
|
-20
|
-1
|
9 396
|
11 156
|
-16
|
1
|
||||||||||||||||||||||||
Corporate income & expense, net from continuing operations
|
-142
|
85
|
nm
|
nm
|
-419
|
-67
|
-525
|
-455
|
||||||||||||||||||||||||
Operating income from continuing operations
|
1 677
|
2 351
|
-29
|
-12
|
8 977
|
11 089
|
-19
|
-2
|
||||||||||||||||||||||||
As % of net sales
|
13.4
|
%
|
18.0
|
%
|
18.2
|
%
|
21.3
|
%
|
||||||||||||||||||||||||
Income from associated companies
|
10
|
580
|
-98
|
-98
|
266
|
1 918
|
-86
|
-86
|
||||||||||||||||||||||||
Interest expense
|
-158
|
-188
|
16
|
11
|
-655
|
-704
|
7
|
2
|
||||||||||||||||||||||||
Other financial income and expense
|
-398
|
13
|
nm
|
nm
|
-454
|
-31
|
nm
|
nm
|
||||||||||||||||||||||||
Taxes
|
-77
|
-308
|
75
|
61
|
-1 106
|
-1 545
|
28
|
10
|
||||||||||||||||||||||||
Net income from continuing operations
|
1 054
|
2 448
|
-57
|
-34
|
7 028
|
10 727
|
-34
|
-18
|
||||||||||||||||||||||||
Net income from discontinued operations
|
2
|
-961
|
nm
|
nm
|
10 766
|
-447
|
nm
|
nm
|
||||||||||||||||||||||||
Net income
|
1 056
|
1 487
|
-29
|
12
|
17 794
|
10 280
|
73
|
91
|
||||||||||||||||||||||||
Basic earnings per share from continuing operations (USD)
|
0.44
|
1.02
|
-57
|
-34
|
2.92
|
4.39
|
-33
|
-17
|
||||||||||||||||||||||||
Basic earnings per share from discontinued operations (USD)
|
0.00
|
-0.40
|
nm
|
nm
|
4.48
|
-0.18
|
nm
|
nm
|
||||||||||||||||||||||||
Total basic earnings per share (USD)
|
0.44
|
0.62
|
-29
|
12
|
7.40
|
4.21
|
76
|
94
|
||||||||||||||||||||||||
Free cash flow from continuing operations2
|
2 942
|
3 955
|
-26
|
9 259
|
10 934
|
-15
|
||||||||||||||||||||||||||
Free cash flow
|
3 002
|
4 419
|
-32
|
9 029
|
10 762
|
-16
|
||||||||||||||||||||||||||
Core2
|
||||||||||||||||||||||||||||||||
Core operating income from continuing operations
|
3 057
|
3 229
|
-5
|
9
|
13 790
|
14 473
|
-5
|
10
|
||||||||||||||||||||||||
As % of net sales
|
24.4
|
%
|
24.7
|
%
|
27.9
|
%
|
27.7
|
%
|
||||||||||||||||||||||||
Core net income from continuing operations
|
2 707
|
2 857
|
-5
|
7
|
12 041
|
12 653
|
-5
|
9
|
||||||||||||||||||||||||
Core net loss/income from discontinued operations
|
-48
|
57
|
nm
|
nm
|
-256
|
102
|
nm
|
nm
|
||||||||||||||||||||||||
Core net income
|
2 659
|
2 914
|
-9
|
3
|
11 785
|
12 755
|
-8
|
6
|
||||||||||||||||||||||||
Core earnings per share from continuing operations (USD)
|
1.14
|
1.19
|
-4
|
8
|
5.01
|
5.19
|
-3
|
10
|
||||||||||||||||||||||||
Core loss/earnings per share from discontinued operations (USD)
|
-0.03
|
0.02
|
nm
|
nm
|
-0.11
|
0.04
|
nm
|
nm
|
||||||||||||||||||||||||
Total core earnings per share (USD)
|
1.11
|
1.21
|
-8
|
4
|
4.90
|
5.23
|
-6
|
7
|
Q4 2015
|
Q4 2014
|
% change
|
FY 2015
|
FY 2014
|
% change
|
|||||||||||||||||||||||||||
USD m
|
USD m
|
USD
|
cc
|
USD m
|
USD m
|
USD
|
cc
|
|||||||||||||||||||||||||
Net sales
|
7 865
|
7 860
|
0
|
9
|
30 445
|
31 791
|
-4
|
6
|
||||||||||||||||||||||||
Operating income
|
1 471
|
1 611
|
-9
|
9
|
7 597
|
8 471
|
-10
|
5
|
||||||||||||||||||||||||
As % of net sales
|
18.7
|
20.5
|
25.0
|
26.6
|
||||||||||||||||||||||||||||
Core operating income
|
2 105
|
1 977
|
6
|
23
|
9 420
|
9 514
|
-1
|
14
|
||||||||||||||||||||||||
As % of net sales
|
26.8
|
25.2
|
30.9
|
29.9
|
Q4 2015
|
Q4 2014
|
% change
|
FY 2015
|
FY 2014
|
% change
|
|||||||||||||||||||||||||||
USD m
|
USD m
|
USD
|
cc
|
USD m
|
USD m
|
USD
|
cc
|
|||||||||||||||||||||||||
Gleevec/Glivec
|
1 219
|
1 237
|
-1
|
4
|
4 658
|
4 746
|
-2
|
5
|
||||||||||||||||||||||||
Tasigna
|
432
|
428
|
1
|
8
|
1 632
|
1 529
|
7
|
16
|
||||||||||||||||||||||||
Subtotal Bcr-Abl franchise
|
1 651
|
1 665
|
-1
|
5
|
6 290
|
6 275
|
0
|
8
|
||||||||||||||||||||||||
Sandostatin
|
413
|
416
|
-1
|
7
|
1 630
|
1 650
|
-1
|
7
|
||||||||||||||||||||||||
Afinitor/Votubia
|
382
|
426
|
-10
|
-4
|
1 607
|
1 575
|
2
|
10
|
||||||||||||||||||||||||
Exjade/Jadenu
|
248
|
243
|
2
|
9
|
917
|
926
|
-1
|
8
|
||||||||||||||||||||||||
Votrient
|
176
|
0
|
nm
|
nm
|
565
|
0
|
nm
|
nm
|
||||||||||||||||||||||||
Tafinlar + Mekinist1
|
147
|
0
|
nm
|
nm
|
453
|
0
|
nm
|
nm
|
||||||||||||||||||||||||
Jakavi
|
119
|
84
|
42
|
59
|
410
|
279
|
47
|
71
|
||||||||||||||||||||||||
Promacta/Revolade
|
133
|
0
|
nm
|
nm
|
402
|
0
|
nm
|
nm
|
||||||||||||||||||||||||
Femara
|
70
|
98
|
-29
|
-21
|
304
|
380
|
-20
|
-11
|
||||||||||||||||||||||||
Zykadia
|
24
|
12
|
100
|
104
|
79
|
31
|
155
|
162
|
||||||||||||||||||||||||
Other
|
203
|
138
|
47
|
59
|
819
|
587
|
40
|
50
|
||||||||||||||||||||||||
Total Oncology
|
3 566
|
3 082
|
16
|
23
|
13 476
|
11 703
|
15
|
24
|
Q4 2015
|
Q4 2014
|
% change
|
FY 2015
|
FY 2014
|
% change
|
|||||||||||||||||||||||||||
USD m
|
USD m
|
USD
|
cc
|
USD m
|
USD m
|
USD
|
cc
|
|||||||||||||||||||||||||
Gilenya
|
742
|
666
|
11
|
18
|
2 776
|
2 477
|
12
|
21
|
||||||||||||||||||||||||
Exelon/Exelon Patch
|
135
|
240
|
-44
|
-37
|
728
|
1 009
|
-28
|
-21
|
||||||||||||||||||||||||
Comtan/Stalevo
|
75
|
89
|
-16
|
-7
|
294
|
371
|
-21
|
-8
|
||||||||||||||||||||||||
Other
|
31
|
59
|
-47
|
-44
|
141
|
243
|
-42
|
-35
|
||||||||||||||||||||||||
Total Neuroscience
|
983
|
1 054
|
-7
|
0
|
3 939
|
4 100
|
-4
|
5
|
Q4 2015
|
Q4 2014
|
% change
|
FY 2015
|
FY 2014
|
% change
|
|||||||||||||||||||||||||||
USD m
|
USD m
|
USD
|
cc
|
USD m
|
USD m
|
USD
|
cc
|
|||||||||||||||||||||||||
Lucentis
|
499
|
588
|
-15
|
-4
|
2 060
|
2 441
|
-16
|
-2
|
||||||||||||||||||||||||
Other
|
12
|
13
|
-8
|
-8
|
50
|
63
|
-21
|
-12
|
||||||||||||||||||||||||
Total Retina
|
511
|
601
|
-15
|
-4
|
2 110
|
2 504
|
-16
|
-3
|
Q4 2015
|
Q4 2014
|
% change
|
FY 2015
|
FY 2014
|
% change
|
|||||||||||||||||||||||||||
USD m
|
USD m
|
USD
|
cc
|
USD m
|
USD m
|
USD
|
cc
|
|||||||||||||||||||||||||
Neoral/Sandimmun(e)
|
144
|
164
|
-12
|
-3
|
570
|
684
|
-17
|
-6
|
||||||||||||||||||||||||
Myfortic
|
115
|
131
|
-12
|
0
|
441
|
543
|
-19
|
-8
|
||||||||||||||||||||||||
Zortress/Certican
|
89
|
85
|
5
|
17
|
335
|
327
|
2
|
17
|
||||||||||||||||||||||||
Cosentyx
|
121
|
0
|
nm
|
nm
|
261
|
0
|
nm
|
nm
|
||||||||||||||||||||||||
Ilaris
|
63
|
54
|
17
|
25
|
236
|
199
|
19
|
30
|
||||||||||||||||||||||||
Other1
|
38
|
45
|
-16
|
-8
|
160
|
173
|
-8
|
2
|
||||||||||||||||||||||||
Total I and D (excl. everolimus stent drug)
|
570
|
479
|
19
|
30
|
2 003
|
1 926
|
4
|
16
|
||||||||||||||||||||||||
Everolimus stent drug
|
58
|
62
|
-6
|
-7
|
134
|
205
|
-35
|
-35
|
||||||||||||||||||||||||
Total I and D
|
628
|
541
|
16
|
26
|
2 137
|
2 131
|
0
|
11
|
Q4 2015
|
Q4 2014
|
% change
|
FY 2015
|
FY 2014
|
% change
|
|||||||||||||||||||||||||||
USD m
|
USD m
|
USD
|
cc
|
USD m
|
USD m
|
USD
|
cc
|
|||||||||||||||||||||||||
Ultibro Breezhaler
|
76
|
51
|
49
|
68
|
260
|
118
|
120
|
157
|
||||||||||||||||||||||||
Onbrez Breezhaler/Arcapta Neohaler
|
38
|
56
|
-32
|
-22
|
166
|
220
|
-25
|
-11
|
||||||||||||||||||||||||
Seebri Breezhaler
|
37
|
42
|
-12
|
1
|
150
|
146
|
3
|
21
|
||||||||||||||||||||||||
COPD portfolio
|
151
|
149
|
1
|
15
|
576
|
484
|
19
|
40
|
||||||||||||||||||||||||
Xolair1
|
197
|
200
|
-2
|
12
|
755
|
777
|
-3
|
14
|
||||||||||||||||||||||||
Other
|
73
|
74
|
-1
|
5
|
263
|
320
|
-18
|
-11
|
||||||||||||||||||||||||
Total Respiratory
|
421
|
423
|
0
|
12
|
1 594
|
1 581
|
1
|
17
|
Q4 2015
|
Q4 2014
|
% change
|
FY 2015
|
FY 2014
|
% change
|
|||||||||||||||||||||||||||
USD m
|
USD m
|
USD
|
cc
|
USD m
|
USD m
|
USD
|
cc
|
|||||||||||||||||||||||||
Galvus
|
294
|
295
|
0
|
12
|
1 140
|
1 224
|
-7
|
8
|
||||||||||||||||||||||||
Entresto
|
5
|
0
|
nm
|
nm
|
21
|
0
|
nm
|
nm
|
||||||||||||||||||||||||
Other
|
0
|
0
|
nm
|
nm
|
0
|
8
|
nm
|
nm
|
||||||||||||||||||||||||
Total Cardio-Metabolic
|
299
|
295
|
1
|
14
|
1 161
|
1 232
|
-6
|
9
|
Q4 2015
|
Q4 2014
|
% change
|
FY 2015
|
FY 2014
|
% change
|
|||||||||||||||||||||||||||
USD m
|
USD m
|
USD
|
cc
|
USD m
|
USD m
|
USD
|
cc
|
|||||||||||||||||||||||||
Diovan
|
292
|
379
|
-23
|
-16
|
1 284
|
2 345
|
-45
|
-40
|
||||||||||||||||||||||||
Exforge
|
249
|
298
|
-16
|
-7
|
1 047
|
1 396
|
-25
|
-15
|
||||||||||||||||||||||||
Voltaren/Cataflam1
|
140
|
172
|
-19
|
-9
|
558
|
632
|
-12
|
0
|
||||||||||||||||||||||||
Ritalin/Focalin
|
80
|
128
|
-38
|
-32
|
365
|
492
|
-26
|
-20
|
||||||||||||||||||||||||
Other2
|
696
|
887
|
-22
|
-9
|
2 774
|
3 675
|
-25
|
-14
|
||||||||||||||||||||||||
Total Established Medicines
|
1 457
|
1 864
|
-22
|
-12
|
6 028
|
8 540
|
-29
|
-21
|
Q4 2015
|
Q4 2014
|
% change
|
FY 2015
|
FY 2014
|
% change
|
|||||||||||||||||||||||||||
USD m
|
USD m
|
USD
|
cc
|
USD m
|
USD m
|
USD
|
cc
|
|||||||||||||||||||||||||
Net sales
|
2 349
|
2 703
|
-13
|
-6
|
9 812
|
10 827
|
-9
|
-1
|
||||||||||||||||||||||||
Operating income
|
132
|
365
|
-64
|
-36
|
794
|
1 597
|
-50
|
-20
|
||||||||||||||||||||||||
As % of net sales
|
5.6
|
13.5
|
8.1
|
14.8
|
||||||||||||||||||||||||||||
Core operating income
|
670
|
895
|
-25
|
-13
|
3 063
|
3 811
|
-20
|
-7
|
||||||||||||||||||||||||
As % of net sales
|
28.5
|
33.1
|
31.2
|
35.2
|
Q4 2015
|
Q4 2014
|
% change
|
FY 2015
|
FY 2014
|
% change
|
|||||||||||||||||||||||||||
USD m
|
USD m
|
USD
|
cc
|
USD m
|
USD m
|
USD
|
cc
|
|||||||||||||||||||||||||
Cataract products
|
715
|
836
|
-14
|
-7
|
2 853
|
3 174
|
-10
|
-2
|
||||||||||||||||||||||||
IOLs
|
267
|
319
|
-16
|
-8
|
1 099
|
1 264
|
-13
|
-4
|
||||||||||||||||||||||||
Vitreoretinal products
|
152
|
158
|
-4
|
3
|
594
|
615
|
-3
|
6
|
||||||||||||||||||||||||
Refractive/Other
|
70
|
72
|
-3
|
3
|
251
|
284
|
-12
|
-5
|
||||||||||||||||||||||||
Total Surgical
|
937
|
1 066
|
-12
|
-5
|
3 698
|
4 073
|
-9
|
-1
|
Q4 2015
|
Q4 2014
|
% change
|
FY 2015
|
FY 2014
|
% change
|
|||||||||||||||||||||||||||
USD m
|
USD m
|
USD
|
cc
|
USD m
|
USD m
|
USD
|
cc
|
|||||||||||||||||||||||||
Glaucoma
|
295
|
331
|
-11
|
-2
|
1 196
|
1 319
|
-9
|
2
|
||||||||||||||||||||||||
Allergy/Otic/Nasal
|
135
|
178
|
-24
|
-21
|
780
|
887
|
-12
|
-8
|
||||||||||||||||||||||||
Infection/Inflammation
|
251
|
279
|
-10
|
-4
|
1 011
|
1 066
|
-5
|
2
|
||||||||||||||||||||||||
Dry Eye/Tears
|
140
|
155
|
-10
|
0
|
583
|
608
|
-4
|
6
|
||||||||||||||||||||||||
Other
|
60
|
81
|
-26
|
-17
|
243
|
331
|
-27
|
-15
|
||||||||||||||||||||||||
Total Ophthalmic Pharmaceuticals
|
881
|
1 024
|
-14
|
-5
|
3 813
|
4 211
|
-9
|
0
|
Q4 2015
|
Q4 2014
|
% change
|
FY 2015
|
FY 2014
|
% change
|
|||||||||||||||||||||||||||
USD m
|
USD m
|
USD
|
cc
|
USD m
|
USD m
|
USD
|
cc
|
|||||||||||||||||||||||||
Contact Lenses
|
393
|
455
|
-14
|
-7
|
1 743
|
1 897
|
-8
|
1
|
||||||||||||||||||||||||
Contact Lens Care
|
138
|
158
|
-13
|
-8
|
558
|
646
|
-14
|
-8
|
||||||||||||||||||||||||
Total Vision Care
|
531
|
613
|
-13
|
-8
|
2 301
|
2 543
|
-10
|
-2
|
Q4 2015
|
Q4 2014
|
% change
|
FY 2015
|
FY 2014
|
% change
|
|||||||||||||||||||||||||||
USD m
|
USD m
|
USD
|
cc
|
USD m
|
USD m
|
USD
|
cc
|
|||||||||||||||||||||||||
Net sales
|
2 306
|
2 512
|
-8
|
0
|
9 157
|
9 562
|
-4
|
7
|
||||||||||||||||||||||||
Operating income
|
216
|
290
|
-26
|
-18
|
1 005
|
1 088
|
-8
|
1
|
||||||||||||||||||||||||
As % of net sales
|
9.4
|
11.5
|
11.0
|
11.4
|
||||||||||||||||||||||||||||
Core operating income
|
397
|
416
|
-5
|
4
|
1 659
|
1 571
|
6
|
17
|
||||||||||||||||||||||||
As % of net sales
|
17.2
|
16.6
|
18.1
|
16.4
|
Q4 2015
|
Q4 2014
|
% change
|
FY 2015
|
FY 2014
|
% change
|
|||||||||||||||
USD m
|
USD m
|
USD
|
cc
|
USD m
|
USD m
|
USD
|
cc
|
|||||||||||||
Net sales
|
0
|
1 558
|
nm
|
nm
|
601
|
5 816
|
nm
|
nm
|
||||||||||||
Operating loss/income
|
-94
|
-1 179
|
nm
|
nm
|
12 477
|
-353
|
nm
|
nm
|
||||||||||||
As % of net sales
|
nm
|
-75.7
|
nm
|
-6.1
|
||||||||||||||||
Core operating loss/income
|
-2
|
93
|
nm
|
nm
|
-225
|
143
|
nm
|
nm
|
||||||||||||
As % of net sales
|
nm
|
6.0
|
|
|
-37.4
|
2.5
|
|
|
·
|
Entresto (sacubitril/valsartan) was approved in the EU for the treatment of adult patients with symptomatic chronic heart failure with reduced ejection fraction (HFrEF).
|
·
|
Cosentyx (secukinumab) was approved in the EU to treat ankylosing spondylitis (AS) and psoriatic arthritis (PsA). Cosentyx is now approved for the treatment of adults with active AS who have responded inadequately to conventional therapy, such as non-steroidal anti-inflammatory drugs, and for the treatment of active PsA in adults when the response to disease-modifying anti-rheumatic drug therapy is unsatisfactory.
|
·
|
Cosentyx was also approved in the US for the AS and PsA indications in January 2016.
|
·
|
The Japanese Ministry of Health, Labour and Welfare approved Cosentyx for the treatment of patients with pustular psoriasis.
|
·
|
The FDA approved the dual combination bronchodilator Utibron Neohaler (indacaterol/glycopyrrolate) inhalation powder for the long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. The FDA also approved Seebri Neohaler (glycopyrrolate) inhalation powder, which is one component of Utibron Neohaler, as a standalone monotherapy for the same COPD indication. Utibron and Seebri are delivered via the low-resistance Neohaler inhaler, which makes it suitable for patients with different severities of airflow limitation. Novartis remains committed to offering new treatment options to patients with COPD in the US. Options for a US launch of Utibron Neohaler, including the potential for partnering, continue to be assessed by Novartis.
|
·
|
The FDA granted regular approval for the combination of Tafinlar + Mekinist (dabrafenib + trametinib) for the treatment of patients with BRAF V600E/K mutation-positive unresectable or metastatic melanoma as detected by an FDA-approved test. This is the first targeted therapy combination demonstrating more than two years of overall survival (OS) in patients with the most aggressive form of skin cancer. The combination was previously approved in the US under the FDA’s accelerated approval program.
|
·
|
The FDA approved Arzerra (ofatumumab) as an extended treatment of patients who are in complete or partial response after at least two lines of therapy for recurrent or progressive chronic lymphocytic leukemia.
|
·
|
The UK’s National Institute for Health and Care Excellence (NICE) recommended Farydak (panobinostat) as a treatment option for adult patients with relapsed and/or refractory multiple myeloma who have received at least two prior treatment regimens including bortezomib and an immunomodulatory agent.
|
·
|
Jakavi (ruxolitinib) was approved in Canada to control hematocrit in adult patients with polycythemia vera resistant to or intolerant of a cytoreductive agent.
|
·
|
The FDA approved an addition to the Jadenu (deferasirox) label allowing the tablets to be crushed and sprinkled on food, thus enabling patients who cannot swallow whole tablets to benefit from the oral formulation.
|
·
|
The CHMP adopted a positive opinion recommending a change to the adult ITP indication for Revolade (eltrombopag) that removes language limiting use only to splenectomised patients who are refractory to other treatments.
|
·
|
Alcon achieved European CE mark for AirOptix Plus HydraGlyde, a monthly contact lens for correction of refractive error with longer lasting lens surface wettability for added comfort.
|
·
|
The FDA and Health Canada granted priority review to the application for Afinitor (everolimus) for use in advanced, progressive, non-functional neuroendocrine tumors (NET) of gastrointestinal or lung origin.
|
·
|
A regulatory application was submitted to the FDA for Xolair (omalizumab) in pediatrics, for the indication of allergic asthma.
|
·
|
The EMA accepted Sandoz’s regulatory submission for biosimilar Enbrel® (etanercept). Sandoz is seeking approval for all indications included in the reference product’s label, including rheumatoid arthritis and psoriasis.
|
·
|
The FDA accepted Sandoz’s regulatory submission for biosimilar Neulasta® (pegfilgrastim). The submission was based on the Phase III PROTECT 2 study, which showed the proposed biosimilar to be both equivalent and non-inferior to Neulasta® for the prevention of neutropenia in patients with breast cancer. Sandoz is seeking approval for the same indication as the reference product.
|
·
|
Late-breaking results for Cosentyx presented at the American College of Rheumatology showed up to 80% of patients with AS had no radiographic progression in the spine as shown by x-ray assessment over two years. This is the first time that data on structural spinal progression in AS have been presented for an IL-17A inhibitor. In addition, at the same meeting, new data was presented for Cosentyx showing no further progression in joint damage in 84% of patients with PsA over two years of treatment.
|
·
|
The results of the MEASURE 1 and MEASURE 2 Phase III studies for Cosentyx in AS were published in The New England Journal of Medicine in December. These pivotal studies demonstrated significant clinical improvements with Cosentyx versus placebo in the signs and symptoms of active AS, and, collectively, the studies form the largest clinical trial program ever conducted in AS, involving 590 patients.
|
·
|
Novartis confirmed that, following interim analysis, the Data Monitoring Committee of the RELAX-AHF-2 study of RLX030 (serelaxin) recommended continuing the trial without changes. Top-line results are expected in 2017, based on the latest projections to obtain the pre-specified number of cardiovascular events needed to complete the study. Timelines were slightly extended after the addition in 2015 of “worsening heart failure” as an additional primary endpoint.
|
·
|
In January 2016, Novartis continued to grow its immuno-oncology pipeline through a collaboration and licensing agreement with Surface Oncology. Through the agreement, Novartis gained access to four pre-clinical programs that target regulatory T cell populations, inhibitory cytokines, and immunosuppressive metabolites in the tumor microenvironment. Novartis now has seven immuno-oncology assets in clinical trials and five more are expected to enter the clinic individually and as combinations by the end of 2016.
|
·
|
The latest findings from two ongoing Phase II studies of CTL019, an investigational chimeric antigen receptor T cell (CART) therapy, were presented at the American Society of Hematology. In a study of relapsed/refractory (r/r) pediatric acute lymphoblastic leukemia (ALL), 55 of 59 patients experienced complete remissions with CTL019. OS was 79% at 12 months, and relapse-free survival was 76% at six months and 55% at 12 months. Additionally, 52 of 59 patients developed Grade 1-4 cytokine-release syndrome (CRS). In a study of CTL019 in certain r/r non-Hodgkin lymphomas, an overall response rate (ORR) of 73% (8/11) was observed in patients with follicular lymphoma and 47% (7/15) in patients with diffuse large B-cell lymphoma (DLBCL). Four patients developed CRS of Grade 3 or higher at peak T cell expansion.
|
·
|
Novartis recently expanded its own global multi-site Phase II clinical trial of CTL019 in pediatric r/r ALL and adult r/r DLBCL with the opening of study sites in Europe. Novartis is processing patient cells for these global studies at its cell-processing facility in Morris Plains, NJ, the first FDA-approved
|
·
|
In the COMFORT-II Phase III study, five-year treatment with Jakavi (ruxolitinib) demonstrated an OS advantage for myelofibrosis patients, despite crossover from best available therapy after week 48.
|
·
|
Top-line results from the head-to-head FLAME trial demonstrated superiority of Ultibro Breezhaler (indacaterol/glycopyrronium) to Seretide® in reducing COPD exacerbations over one year of treatment. First results confirmed that Ultibro Breezhaler is an effective steroid-free option that both reduces exacerbations and improves lung function in COPD patients with one or more exacerbations in the past year, compared to Seretide®. Full study results are due in 2016.
|
·
|
In the Phase III RATIFY (CALGB 10603) trial, adult patients under 60 years of age with newly-diagnosed FLT3-mutated acute myeloid leukemia who received PKC412 (midostaurin) plus standard induction and consolidation chemotherapy, followed by PKC412 for up to a year, experienced a 23% improvement in OS (hazard ratio = 0.77, P = 0.0074) compared to those treated with standard induction and consolidation chemotherapy alone. No statistically significant differences were observed in the overall rate of Grade 3 or higher hematologic and non-hematologic adverse events. The data will serve as the basis for worldwide regulatory submissions in the first half of 2016.
|
·
|
Novartis determined that the SUPPORT and ASPIRE studies do not support registration of Promacta/Revolade (eltrombopag) in intermediate-1, intermediate-2 and high-risk myelodysplastic syndrome and/or acute myeloid leukemia. Novartis is still evaluating the data from both trials to assess whether ongoing development of Promacta/Revolade in these patient populations is warranted.
|
·
|
Results from the pivotal Phase III RADIANT-4 trial of Afinitor in advanced, progressive, non-functional NET of gastrointestinal or lung origin were published in The Lancet.
|
·
|
At Society of Melanoma Research, results were presented from the largest pooled data analysis conducted of 617 patients with BRAF V600E/K mutation-positive unresectable or metastatic melanoma treated with the combination of Tafinlar + Mekinist. The aim of the analysis was to identify baseline and post-baseline factors that could have an impact on survival. The analysis showed that patients experienced longer progression-free survival (PFS) and OS when baseline lactate dehydrogenase (LDH) levels were normal as compared to those with elevated LDH levels. The results further validate that the combination Tafinlar + Mekinist is an effective option for BRAF+ patients with a better prognosis indicated by a normal LDH level. The safety results from the studies in this analysis were consistent with the profile observed to date for the combination; no new safety concerns were observed.
|
·
|
Results from the pivotal Phase III PANORAMA-1 study of Farydak in combination with bortezomib and dexamethasone in patients with multiple myeloma who have received at least two prior regimens, including bortezomib and an immunomodulatory agent, showed a progression-free survival benefit favoring the Farydak combination. These results were published online in Blood.
|
·
|
Results from the Phase III BELLE-2 trial presented at the San Antonio Breast Cancer Symposium showed BKM120 (buparlisib) plus fulvestrant led to 6.9 months of PFS compared to 5.0 months for placebo plus fulvestrant. The subpopulation of patients with ctDNA PIK3CA mutation experienced a 3.8 month PFS improvement. These results validate the role of combination therapy for patients with PI3K mutant ER+, HER2- advanced breast cancer. The results are being discussed with global regulatory authorities.
|
·
|
The Phase III study of single agent OMB157 (ofatumumab) compared to single agent rituximab in patients with follicular non-Hodgkin's lymphoma that has relapsed at least 6 months after completion of treatment with a rituximab-containing regimen will be stopped early. The decision was made after a planned interim analysis performed by an independent Data Monitoring Committee showed that it was unlikely that ofatumumab would show superiority if the trial were to be completed as planned.
|
·
|
Novartis has acquired all remaining rights to OMB157 (ofatumumab) from GSK, including rights for relapsing multiple sclerosis (RMS) and other autoimmune indications. The transaction was closed on December 21, 2015. We expect to begin a Phase III trial in 2016.
|
·
|
The six-month data for the Lucentis (ranibizumab) MINERVA study, a 12-month, randomized, double-masked, sham-controlled, multi-center study to evaluate the efficacy and safety of 0.5 mg ranibizumab intravitreal injections in patients with rare diseases causing visual impairment due to VEGF-driven choroidal neovascularization (CNV) have been analyzed. The results support the extension of Lucentis indications and a submission in the EU is planned for the first quarter of 2016.
|
·
|
Genentech entered into an agreement with Novartis to participate in certain rights related to the Novartis licensing and commercialization agreement with Ophthotech Corporation for OAP030 (pegpleranib, also known as Fovista). We continue to hold the license for the exclusive rights to develop and market OAP030 outside of the US and will remain responsible for the development and commercialization for OAP030 outside of the US. Genentech will share certain risks and benefits with Novartis.
|
·
|
In a Phase IIb study in severe, uncontrolled asthma patients, QGE031 (ligelizumab) failed to demonstrate efficacy following 16 weeks of treatment when added to high-dose inhaled corticosteroids plus long-acting β2-agonists. The ongoing QGE031 Phase II program in chronic spontaneous urticaria will be continued as planned.
|
·
|
Alcon launched Contoura Vision, a topography-guided LASIK treatment designed to provide surgeons the ability to perform more personalized laser procedures based on the unique corneal topography of each eye.
|
Product
|
Active ingredient/
Descriptor |
Indication
|
Approval date
|
Arzerra
|
Ofatumumab
|
Extended treatment of patients who are in complete or partial response after at least two lines of therapy for recurrent or progressive chronic lymphocytic leukemia
|
US - Jan. 2016
|
Tafinlar + Mekinist
|
Dabrafenib + trametinib
|
BRAF V600+ metastatic melanoma
|
US - Nov. 2015 (regular approval, based on overall survival data)
|
Entresto
(LCZ696)
|
Sacubitril/valsartan
|
Chronic heart failure with reduced ejection fraction
|
EU - Nov. 2015
|
Cosentyx
(AIN457)
|
Secukinumab
|
Psoriatic arthritis
|
EU - Nov. 2015
US - Jan. 2016
|
Cosentyx
|
Secukinumab
|
Ankylosing spondylitis
|
EU - Nov. 2015
US - Jan. 2016
|
Cosentyx
|
Secukinumab
|
Pustular psoriasis
|
JP - Dec. 2015
|
Seebri Neohaler
(NVA237)
|
Glycopyrrolate
|
COPD
|
US - Oct. 2015
|
Utibron Neohaler
(QVA149)
|
Indacaterol/glycopyrrolate
|
COPD
|
US - Oct. 2015
|
AirOptix Plus HydraGlyde
|
Contact lens
|
Refractive error
|
EU - Dec. 2015
|
Completed submissions
|
|||||
Product
|
Indication
|
US
|
EU
|
Japan
|
News update
|
Afinitor
|
Advanced progressive, non-functioning GI or lung NET
|
Q3 2015
|
Q3 2015
|
Q3 2015
|
- FDA granted the application priority review
|
Arzerra
|
Chronic lymphocytic leukemia (extended treatment)
|
Approved
|
Q3 2015
|
||
Jadenu
|
Iron overload
|
Approved
|
Q1 2015
|
||
Promacta/ Revolade
|
Pediatric chronic immune thrombocyto-penia
|
Approved (PfOS)
|
Q1 2015
|
||
Severe aplastic anemia
|
Approved
|
Approved
|
|||
Tafinlar + Mekinist
|
BRAF V600+ metastatic melanoma
|
Approved
|
Approved
|
Q2 2015
|
|
Zykadia
(LDK378)
|
ALK+ advanced non-small cell lung cancer (NSCLC), post crizotinib
|
Approved
|
Approved
|
Q2 2015
|
- Orphan Drug Application approved in Japan
|
Project/ Compound
|
Potential indication/
Disease area |
First planned submissions
|
Current Phase
|
News update
|
ABL001
|
Chronic myeloid leukemia
|
≥ 2020
|
I
|
|
AMG 334
|
Migraine
|
III
|
- Partnership agreement with Amgen signed on Aug. 28, 2015
|
|
ASB183
|
Solid and hematologic tumors
|
≥ 2020
|
I
|
|
Ilaris (ACZ885)
|
Hereditary periodic fevers (crFMF, HIDS, TRAPS)
|
2016
|
III
|
- Interim data expected to be presented at medical meetings in 2016
- Study fully enrolled
|
ACZ885
(canakinumab) |
Secondary prevention of cardiovascular events
|
2017
|
III
|
- Study fully enrolled
|
Afinitor/Votubia
|
TSC seizure
|
2016
|
III
|
|
Diffuse large B-cell lymphoma
|
2016
|
III
|
- Sufficient follow-up to provide mature DFS results for a 2016 filing
|
|
Arzerra
|
Chronic lymphocytic leukemia (relapse)
|
2016
|
III
|
|
Non-Hodgkin’s lymphoma (refractory)
|
2017
|
III
|
||
BAF312
|
Secondary progressive MS
|
2019
|
III
|
- Phase III results expected mid-2016
|
BGJ398
|
Solid tumors
|
≥ 2020
|
II
|
|
BKM120 + fulvestrant
|
Metastatic breast cancer ER+ AI resistant mTOR naïve 2nd line
|
2016
|
III
|
- BELLE-2 data presented at SABCS. Submission will be based on 2nd interim survival analysis
|
Metastatic breast cancer ER+ post AI and mTOR inhibitor 3rd line
|
2016
|
III
|
- Submission will be based on final PFS analysis
|
|
BKM120
|
Solid tumors
|
≥ 2020
|
I
|
|
BYL719
|
Solid tumors
|
≥ 2020
|
I
|
BYL719 + fulvestrant
|
HR+/HER2- postmenopausal advanced breast cancer 2nd line
|
2019
|
III
|
|
BYM338
|
Sporadic inclusion body myositis
|
2016
|
III
|
|
Hip fracture
|
≥ 2020
|
II
|
||
Sarcopenia
|
≥ 2020
|
II
|
||
CAD106
|
Alzheimer’s disease
|
≥ 2020
|
II / III
|
|
CJM112
|
Immune disorders
|
≥ 2020
|
II
|
|
CNP520
|
Alzheimer’s disease
|
≥ 2020
|
I/II
|
- Partnership agreement with Amgen signed on Aug. 28, 2015
|
Cosentyx (AIN457)
|
Non-radiographic axial spondyloarthritis
|
2018
|
III
|
|
CTL019
|
Pediatric acute lymphoblastic leukemia
|
2017
|
II
|
|
Diffuse large B-cell lymphoma
|
2017
|
II
|
||
EGF816
|
Solid tumors
|
2018
|
I / II
|
|
EMA401
|
Neuropathic pain
|
≥ 2020
|
II
|
- Acquisition of Spinifex closed Jul. 24, 2015
|
Entresto
(LCZ696)
|
Chronic heart failure with preserved ejection fraction
|
2019
|
III
|
|
Post-acute myocardial infarction
|
≥ 2020
|
III
|
||
FCR001
|
Renal transplant
|
≥ 2020
|
II
|
|
Gilenya
|
Chronic inflammatory demyelinating polyradiculoneuropathy
|
2017
|
III
|
|
HSC835
|
Stem cell transplantation
|
≥ 2020
|
II
|
|
INC280
|
NSCLC
|
2018
|
II
|
|
KAE609
|
Malaria
|
≥ 2020
|
II
|
|
KAF156
|
Malaria
|
2019
|
II
|
|
LCI699
|
Cushing’s disease
|
2017
|
III
|
|
LEE011 + letrozole
|
HR+/HER2- postmenopausal advanced breast cancer 1st line
|
2016
|
III
|
- Phase III registration study fully enrolled
|
LEE011 + tamoxifen + goserelin or
NSAI + goserelin |
HR+/HER2- premenopausal advanced breast cancer 1st line
|
2018
|
III
|
- Phase III registration study enrolling
|
LEE011 + fulvestrant
|
HR+/HER2- postmenopausal advanced breast cancer 1st/2nd line
|
2018
|
III
|
- Accelerated enrollment in trial
|
LEE011
|
Solid tumors
|
2020
|
I
|
- Pending study initiation
|
LJM716
|
Solid tumors
|
≥ 2020
|
I
|
|
LJN452
|
Non-alcoholic steatohepatitis (NASH)
|
≥ 2020
|
II
|
|
Lucentis
|
Choroidal neovascularization (CNV) in rare diseases
|
2016
|
III
|
- Planned EU submission in Q1 2016 for an indication extension for CNV in rare diseases
|
Retinopathy of prematurity
|
2018
|
III
|
- Phase III trial started Dec 2015
|
|
OAP030 (pegpleranib;
also known as Fovista, E10030) |
Neovascular age-related macular degeneration (nAMD)
|
2017
|
III
|
- Enrollment of second pivotal trial completed in Oct. 2015
|
OMB157 (ofatumumab)
|
Relapsing multiple sclerosis (RMS)
|
2019
|
II
|
- Novartis signed an agreement to acquire all remaining rights to GSK’s ofatumumab on Aug. 21, 2015; transaction closed on Dec. 21, 2015
- Phase III trial expected to begin in mid-2016
|
PIM447
|
Hematologic tumors
|
≥2020
|
I
|
|
PKC412
|
Aggressive systemic mastocytosis
|
2016
|
II
|
|
Acute myeloid leukemia
|
2016
|
III
|
- Pivotal data presented at ASH
|
|
QAW039
|
Asthma
|
2019
|
III
|
|
Atopic dermatitis
|
≥ 2020
|
II
|
||
QAX576
|
Allergic diseases
|
≥ 2020
|
II
|
|
QGE031
|
CSU/IU
|
≥ 2020
|
II
|
|
QMF149
|
Asthma
|
2018
|
III
|
|
QVM149
|
Asthma
|
2018
|
III
|
- FPFV achieved in Dec. 2015
|
RLX030
(serelaxin) |
Acute heart failure
|
2017
|
III
|
|
Signifor LAR
|
Cushing’s disease
|
2016
|
III
|
|
Tafinlar + Mekinist
|
BRAF V600+ NSCLC
|
2016
|
II
|
- Trial ongoing
|
BRAF V600+ melanoma (adjuvant)
|
2017
|
III
|
- Trial ongoing
|
|
BRAF V600+ colorectal cancer
|
≥ 2020
|
I/II
|
||
Tasigna
|
CML treatment-free remission
|
2016
|
II
|
- Study fully enrolled
|
VAY736
|
Primary Sjoegren’s syndrome
|
≥ 2020
|
II
|
|
Votrient
|
Renal cell carcinoma (adjuvant)
|
2016
|
III
|
- The number of events required to conduct the primary analysis has been reached
|
Zykadia
(LDK378)
|
ALK+ advanced NSCLC
(1st line, treatment naïve) |
2017
|
III
|
- Phase III study enrollment completed
|
ALK+ NSCLC
(brain metastases)
|
2019
|
II
|
- Extended enrollment period
|
Project/ Compound
|
Potential indication/
Disease area |
Planned submissions
|
Current Phase
|
News update
|
SURGICAL
|
||||
AcrySof IQ ReSTOR Toric IOL 2.5D
|
Cataract
|
US 2016
|
Advanced
|
|
AcrySof IQ ReSTOR 3.0D Toric IOL
|
Cataract
|
US 2014
|
Submitted
|
|
AcrySof IQ Aspheric IOL with UltraSert
|
Pre-loaded IOL delivery device
|
JP 2015
|
Submitted
|
|
OPHTHALMIC PHARMACEUTICALS
|
||||
RTH258
|
Retina (wet AMD)
|
Phase III
|
- First Phase III clinical studies initiated Dec. 2014
- Second Phase III clinical studies initiated Q3 2015
|
|
Jetrea Ready- Diluted Ocriplasmin Injection
|
Retina (vitreomacular traction)
|
JP 2017
|
Phase III
|
|
Nepafenac (0.3%)
|
Retina (macular edema)
|
US 2018
EU 2015
|
Submitted
|
VISION CARE
|
||||
AirOptix Plus HydraGlyde contact lens
|
Refractive
|
US 2016
JP 2016 |
Advanced
Advanced
|
- Received CE mark in Europe in Q4 2015
|
Project/ Compound
|
Potential indication/
Disease area |
Submissions status
|
Current Phase
|
News update
|
GP2013 (rituximab)
|
Non-Hodgkin lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis (RA), granulomatosis with polyangiitis (also known as Wegener’s granulomatosis), and microscopic polyangiitis and others (same as originator)
|
II and III
|
- Recruitment in Phase III follicular lymphoma & Phase II RA trials completed in Jan. 2015 and Jun. 2015 respectively
|
|
GP2015
(etanercept)
|
Arthritidies (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis), plaque psoriasis and others (same as originator)
|
EU and US
|
Submitted
|
- File accepted by FDA and EMA in Q4 2015
|
GP2017 (adalimumab)
|
Arthritidies (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis), plaque psoriasis and others (same as originator)
|
III
|
- Recruitment in Phase III psoriasis completed in Mar. 2015
|
|
LA-EP2006 (pegfilgrastim)
|
Chemotherapy-induced neutropenia and others (same as originator)
|
US
|
Submitted
|
- File accepted by FDA in Q4 2015
|
HX575
(epoetin alfa)
|
Chronic kidney disease, chemotherapy-induced anemia and others (same as
originator)
|
III
|
- Trial complete
|
|
HX575 s.c.
(epoetin alfa)
|
Chronic kidney disease
|
EU (extension
nephrology,
approved as
Binocrit since 2007)
|
Submitted
|
- File accepted by EMA in Q4 2015
|
Q4 2015 USD m |
Q4 2014 USD m |
Change USD m |
|||||
Net sales to third parties from continuing operations | 12 520 | 13 075 | -555 | ||||
Sales to discontinued segments | 0 | 55 | -55 | ||||
Net sales from continuing operations | 12 520 | 13 130 | -610 | ||||
Other revenues | 284 | 224 | 60 | ||||
Cost of goods sold | -4 549 | -4 416 | -133 | ||||
Gross profit from continuing operations | 8 255 | 8 938 | -683 | ||||
Marketing & Sales | -3 175 | -3 229 | 54 | ||||
Research & Development | -2 472 | -2 537 | 65 | ||||
General & Administration | -710 | -736 | 26 | ||||
Other income | 596 | 606 | -10 | ||||
Other expense | -817 | -691 | -126 | ||||
Operating income from continuing operations | 1 677 | 2 351 | -674 | ||||
Income from associated companies | 10 | 580 | -570 | ||||
Interest expense | -158 | -188 | 30 | ||||
Other financial income and expense | -398 | 13 | -411 | ||||
Income before taxes from continuing operations | 1 131 | 2 756 | -1 625 | ||||
Taxes | -77 | -308 | 231 | ||||
Net income from continuing operations | 1 054 | 2 448 | -1 394 | ||||
Net income/loss from discontinued operations | 2 | -961 | 963 | ||||
Net income | 1 056 | 1 487 | -431 | ||||
Attributable to: | |||||||
Shareholders of Novartis AG
|
1 054 | 1 491 | -437 | ||||
Non-controlling interests
|
2 | -4 | 6 | ||||
Weighted average number of shares outstanding – Basic (million) | 2 385 | 2 408 | -23 | ||||
Basic earnings per share from continuing operations (USD)1 | 0.44 | 1.02 | -0.58 | ||||
Basic earnings per share from discontinued operations (USD)1 | 0.00 | -0.40 | 0.40 | ||||
Total basic earnings per share (USD)1 | 0.44 | 0.62 | -0.18 | ||||
Weighted average number of shares outstanding – Diluted (million) | 2 418 | 2 449 | -31 | ||||
Diluted earnings per share from continuing operations (USD)1 | 0.44 | 1.00 | -0.56 | ||||
Diluted earnings per share from discontinued operations (USD)1 | 0.00 | -0.39 | 0.39 | ||||
Total diluted earnings per share (USD)1 | 0.44 | 0.61 | -0.17 | ||||
1 Earnings per share (EPS) is calculated on the amount of net income attributable to shareholders of Novartis AG.
|
|||||||
|
|||||||
FY 2015 USD m |
FY 2014 USD m |
Change USD m |
|||||
Net sales to third parties from continuing operations | 49 414 | 52 180 | -2 766 | ||||
Sales to discontinued segments | 26 | 239 | -213 | ||||
Net sales from continuing operations | 49 440 | 52 419 | -2 979 | ||||
Other revenues | 947 | 1 215 | -268 | ||||
Cost of goods sold | -17 404 | -17 345 | -59 | ||||
Gross profit from continuing operations | 32 983 | 36 289 | -3 306 | ||||
Marketing & Sales | -11 772 | -12 377 | 605 | ||||
Research & Development | -8 935 | -9 086 | 151 | ||||
General & Administration | -2 475 | -2 616 | 141 | ||||
Other income | 2 049 | 1 391 | 658 | ||||
Other expense | -2 873 | -2 512 | -361 | ||||
Operating income from continuing operations | 8 977 | 11 089 | -2 112 | ||||
Income from associated companies | 266 | 1 918 | -1 652 | ||||
Interest expense | -655 | -704 | 49 | ||||
Other financial income and expense | -454 | -31 | -423 | ||||
Income before taxes from continuing operations | 8 134 | 12 272 | -4 138 | ||||
Taxes | -1 106 | -1 545 | 439 | ||||
Net income from continuing operations | 7 028 | 10 727 | -3 699 | ||||
Net income/loss from discontinued operations | 10 766 | -447 | 11 213 | ||||
Net income | 17 794 | 10 280 | 7 514 | ||||
Attributable to: | |||||||
Shareholders of Novartis AG
|
17 783 | 10 210 | 7 573 | ||||
Non-controlling interests
|
11 | 70 | -59 | ||||
Weighted average number of shares outstanding – Basic (million) | 2 403 | 2 426 | -23 | ||||
Basic earnings per share from continuing operations (USD)1 | 2.92 | 4.39 | -1.47 | ||||
Basic earnings per share from discontinued operations (USD)1 | 4.48 | -0.18 | 4.66 | ||||
Total basic earnings per share (USD)1 | 7.40 | 4.21 | 3.19 | ||||
Weighted average number of shares outstanding – Diluted (million) | 2 438 | 2 470 | -32 | ||||
Diluted earnings per share from continuing operations (USD)1 | 2.88 | 4.31 | -1.43 | ||||
Diluted earnings per share from discontinued operations (USD)1 | 4.41 | -0.18 | 4.59 | ||||
Total diluted earnings per share (USD)1 | 7.29 | 4.13 | 3.16 | ||||
1 Earnings per share (EPS) is calculated on the amount of net income attributable to shareholders of Novartis AG.
|
|||||||
|
Q4 2015 USD m |
Q4 2014 USD m |
Change USD m |
|||||
Net income | 1 056 | 1 487 | -431 | ||||
Other comprehensive income to be eventually recycled into the consolidated income statement: | |||||||
Fair value adjustments on financial instruments, net of taxes
|
46 | 78 | -32 | ||||
Novartis share of other items recorded in comprehensive income recognized by associated companies, net of taxes
|
0 | 5 | -5 | ||||
Translation effects
|
-730 | -873 | 143 | ||||
Total of items to eventually recycle
|
-684 | -790 | 106 | ||||
Other comprehensive income never to be recycled into the consolidated income statement: | |||||||
Net actuarial gains from defined benefit plans, net of taxes
|
305 | 320 | -15 | ||||
Comprehensive income | 677 | 1 017 | -340 | ||||
Attributable to: | |||||||
Shareholders of Novartis AG
|
675 | 1 022 | -347 | ||||
Continuing operations
|
665 | 2 022 | -1 357 | ||||
Discontinued operations
|
10 | -1 000 | 1 010 | ||||
Non-controlling interests
|
2 | -5 | 7 | ||||
FY 2015 USD m |
FY 2014 USD m |
Change USD m |
|||||
Net income | 17 794 | 10 280 | 7 514 | ||||
Other comprehensive income to be eventually recycled into the consolidated income statement: | |||||||
Fair value adjustments on financial instruments, net of taxes
|
48 | 110 | -62 | ||||
Novartis share of other items recorded in comprehensive income recognized by associated companies, net of taxes
|
-48 | -5 | -43 | ||||
Translation effects
|
-1 662 | -2 220 | 558 | ||||
Total of items to eventually recycle
|
-1 662 | -2 115 | 453 | ||||
Other comprehensive income never to be recycled into the consolidated income statement: | |||||||
Net actuarial losses from defined benefit plans, net of taxes
|
-147 | -822 | 675 | ||||
Comprehensive income | 15 985 | 7 343 | 8 642 | ||||
Attributable to: | |||||||
Shareholders of Novartis AG
|
15 977 | 7 274 | 8 703 | ||||
Continuing operations
|
5 238 | 7 820 | -2 582 | ||||
Discontinued operations
|
10 739 | -546 | 11 285 | ||||
Non-controlling interests
|
8 | 69 | -61 | ||||
Dec 31, 2015 USD m |
Dec 31, 2014 USD m |
Change USD m |
|||||
Assets | |||||||
Non-current assets | |||||||
Property, plant & equipment | 15 982 | 15 983 | -1 | ||||
Goodwill | 31 174 | 29 311 | 1 863 | ||||
Intangible assets other than goodwill | 34 217 | 23 832 | 10 385 | ||||
Financial and other non-current assets | 27 338 | 18 700 | 8 638 | ||||
Total non-current assets | 108 711 | 87 826 | 20 885 | ||||
Current assets | |||||||
Inventories | 6 226 | 6 093 | 133 | ||||
Trade receivables | 8 180 | 8 275 | -95 | ||||
Other current assets | 2 992 | 2 530 | 462 | ||||
Cash and cash equivalents, marketable securities, commodities and derivatives | 5 447 | 13 862 | -8 415 | ||||
Assets related to discontinued operations and held for sale | 0 | 6 801 | -6 801 | ||||
Total current assets | 22 845 | 37 561 | -14 716 | ||||
Total assets | 131 556 | 125 387 | 6 169 | ||||
Equity and liabilities | |||||||
Equity attributable to Novartis AG shareholders | 77 046 | 70 766 | 6 280 | ||||
Non-controlling interests | 76 | 78 | -2 | ||||
Total equity | 77 122 | 70 844 | 6 278 | ||||
Non-current liabilities | |||||||
Financial debts | 16 327 | 13 799 | 2 528 | ||||
Other non-current liabilities | 14 399 | 13 771 | 628 | ||||
Total non-current liabilities | 30 726 | 27 570 | 3 156 | ||||
Current liabilities | |||||||
Trade payables | 5 668 | 5 419 | 249 | ||||
Financial debts and derivatives | 5 604 | 6 612 | -1 008 | ||||
Other current liabilities | 12 436 | 12 524 | -88 | ||||
Liabilities related to discontinued operations and held for sale | 0 | 2 418 | -2 418 | ||||
Total current liabilities | 23 708 | 26 973 | -3 265 | ||||
Total liabilities | 54 434 | 54 543 | -109 | ||||
Total equity and liabilities | 131 556 | 125 387 | 6 169 | ||||
|
Q4 2015 USD m |
Q4 2014 USD m |
Change USD m |
|||||
Consolidated equity at October 1 | 76 785 | 71 424 | 5 361 | ||||
Comprehensive income | 677 | 1 017 | -340 | ||||
Purchase of treasury shares | -1 967 | -1 891 | -76 | ||||
Decrease of treasury share repurchase obligation under a share buy-back trading plan | 1 533 | 17 | 1 516 | ||||
Increase in equity from exercise of options and employee transactions | 10 | 3 | 7 | ||||
Equity-based compensation | 83 | 277 | -194 | ||||
Change in non-controlling interests | 1 | -3 | 4 | ||||
Consolidated equity at December 31 | 77 122 | 70 844 | 6 278 | ||||
|
FY 2015 USD m |
FY 2014 USD m |
Change USD m |
|||||
Consolidated equity at January 1 | 70 844 | 74 472 | -3 628 | ||||
Comprehensive income | 15 985 | 7 343 | 8 642 | ||||
Purchase of treasury shares | -6 119 | -6 926 | 807 | ||||
Decrease/(Increase) of treasury share repurchase obligation under a share buy-back trading plan | 658 | -658 | 1 316 | ||||
Increase in equity from exercise of options and employee transactions | 1 592 | 2 400 | -808 | ||||
Dividends related to shareholders of Novartis AG | -6 643 | -6 810 | 167 | ||||
Equity-based compensation | 815 | 1 143 | -328 | ||||
Change in non-controlling interests | -10 | -120 | 110 | ||||
Consolidated equity at December 31 | 77 122 | 70 844 | 6 278 | ||||
|
Q4 2015 USD m |
Q4 2014 USD m |
Change USD m |
|||||
Net income from continuing operations | 1 054 | 2 448 | -1 394 | ||||
Reversal of non-cash items | |||||||
Taxes
|
77 | 308 | -231 | ||||
Depreciation, amortization and impairments
|
1 429 | 1 291 | 138 | ||||
Change in provisions and other non-current liabilities
|
518 | 316 | 202 | ||||
Income from associated companies
|
-10 | -580 | 570 | ||||
Net financial income
|
556 | 175 | 381 | ||||
Other
|
-70 | -118 | 48 | ||||
Net income adjusted for non-cash items | 3 554 | 3 840 | -286 | ||||
Interest and other financial receipts | 73 | 394 | -321 | ||||
Interest and other financial payments | -150 | -168 | 18 | ||||
Taxes paid1 | -528 | -559 | 31 | ||||
Cash flows before working capital changes from continuing operations | 2 949 | 3 507 | -558 | ||||
Payments out of provisions and other net cash movements in non-current liabilities | -291 | -251 | -40 | ||||
Change in net current assets and other operating cash flow items | 1 439 | 1 467 | -28 | ||||
Cash flows from operating activities from continuing operations | 4 097 | 4 723 | -626 | ||||
Cash flows from operating activities from discontinued operations 1 | 60 | 482 | -422 | ||||
Total cash flows from operating activities | 4 157 | 5 205 | -1 048 | ||||
Purchase of property, plant & equipment | -753 | -830 | 77 | ||||
Purchase of intangible, financial and other non-current assets | -561 | -304 | -257 | ||||
Proceeds from sales of property, plant & equipment, intangible, financial and other non-current assets | 159 | 366 | -207 | ||||
Acquisitions of businesses | -135 | -350 | 215 | ||||
Change in marketable securities, commodities and net investments in associated companies | -187 | 331 | -518 | ||||
Cash flows used in investing activities from continuing operations | -1 477 | -787 | -690 | ||||
Cash flows used in investing activities from discontinued operations 1 | -213 | -132 | -81 | ||||
Total cash flows used in investing activities | -1 690 | -919 | -771 | ||||
Change in current and non-current financial debts | -731 | 1 157 | -1 888 | ||||
Treasury share transactions, net | -2 073 | -1 899 | -174 | ||||
Other financing cash flows | 29 | 0 | 29 | ||||
Cash flows used in financing activities | -2 775 | -742 | -2 033 | ||||
Net translation effect on cash and cash equivalents | -346 | -162 | -184 | ||||
Change in cash and cash equivalents | -654 | 3 382 | -4 036 | ||||
Cash and cash equivalents at October 1 | 5 328 | 9 641 | -4 313 | ||||
Cash and cash equivalents at December 31 | 4 674 | 13 023 | -8 349 | ||||
1 The total tax payment in Q4 2015 amounted to USD 651 million (Q4 2014: USD 692 million) of which a refund of USD 70 million (Q4 2014: payment of USD 19 million) was included in the cash flows from operating activities of discontinued operations and a USD 193 million payment (Q4 2014: USD 114 million) in the cash flows used in investing activities of discontinued operations.
|
FY 2015 USD m |
FY 2014 USD m |
Change USD m |
|||||
Net income from continuing operations | 7 028 | 10 727 | -3 699 | ||||
Reversal of non-cash items | |||||||
Taxes
|
1 106 | 1 545 | -439 | ||||
Depreciation, amortization and impairments
|
5 575 | 4 751 | 824 | ||||
Change in provisions and other non-current liabilities
|
1 642 | 1 490 | 152 | ||||
Income from associated companies
|
-266 | -1 918 | 1 652 | ||||
Net financial income
|
1 109 | 735 | 374 | ||||
Other
|
-96 | 122 | -218 | ||||
Net income adjusted for non-cash items | 16 098 | 17 452 | -1 354 | ||||
Interest and other financial receipts | 1 180 | 1 067 | 113 | ||||
Interest and other financial payments | -669 | -692 | 23 | ||||
Taxes paid1 | -2 454 | -2 179 | -275 | ||||
Cash flows before working capital changes from continuing operations | 14 155 | 15 648 | -1 493 | ||||
Payments out of provisions and other net cash movements in non-current liabilities | -1 207 | -1 125 | -82 | ||||
Change in net current assets and other operating cash flow items | -863 | -625 | -238 | ||||
Cash flows from operating activities from continuing operations | 12 085 | 13 898 | -1 813 | ||||
Cash flows used in operating activities from discontinued operations 1 | -188 | -1 | -187 | ||||
Total cash flows from operating activities | 11 897 | 13 897 | -2 000 | ||||
Purchase of property, plant & equipment | -2 367 | -2 624 | 257 | ||||
Purchase of intangible, financial and other non-current assets | -1 484 | -1 079 | -405 | ||||
Proceeds from sales of property, plant & equipment, intangible, financial and other non-current assets | 1 025 | 739 | 286 | ||||
Acquisitions of businesses | -16 507 | -331 | -16 176 | ||||
Change in marketable securities, commodities and net investments in associated companies | -333 | 3 287 | -3 620 | ||||
Cash flows used in investing activities from continuing operations | -19 666 | -8 | -19 658 | ||||
Cash flows from investing activities from discontinued operations 1 | 8 882 | 889 | 7 993 | ||||
Total cash flows used in/from investing activities | -10 784 | 881 | -11 665 | ||||
Dividends related to shareholders of Novartis AG | -6 643 | -6 810 | 167 | ||||
Change in current and non-current financial debts | 1 961 | 3 318 | -1 357 | ||||
Treasury share transactions, net | -4 490 | -4 515 | 25 | ||||
Other financing cash flows | -4 | -140 | 136 | ||||
Cash flows used in financing activities | -9 176 | -8 147 | -1 029 | ||||
Net translation effect on cash and cash equivalents | -286 | -295 | 9 | ||||
Change in cash and cash equivalents | -8 349 | 6 336 | -14 685 | ||||
Cash and cash equivalents at January 1 | 13 023 | 6 687 | 6 336 | ||||
Cash and cash equivalents at December 31 | 4 674 | 13 023 | -8 349 | ||||
1 In 2015, the total tax payment amounted to USD 3.3 billion (2014: USD 2.6 billion) of which a refund of USD 94 million (2014: payment of USD 7 million) was included in the cash flows used in operating activities of discontinued operations and a USD 965 million payment (2014: USD 459 million) in the cash flows from investing activities of discontinued operations.
|
Number of outstanding shares (in millions) | Issued share capital and reserves attributable to Novartis AG shareholders | ||||||||||||
2015 |
2014 |
Change |
FY 2015 USD m |
FY 2014 USD m |
Change USD m |
||||||||
Balance at beginning of year | 2 398.6 | 2 426.1 | -27.5 | 70 766 | 74 343 | -3 577 | |||||||
Shares acquired to be held in Group Treasury | -9.6 | -46.8 | 37.2 | -897 | -4 057 | 3 160 | |||||||
Shares acquired to be cancelled | -49.9 | -27.0 | -22.9 | -4 805 | -2 396 | -2 409 | |||||||
Other share purchases | -4.1 | -5.4 | 1.3 | -417 | -473 | 56 | |||||||
Increase in equity from exercise of options and employee transactions | 27.0 | 41.4 | -14.4 | 1 592 | 2 400 | -808 | |||||||
Equity-based compensation | 11.9 | 10.3 | 1.6 | 815 | 1 143 | -328 | |||||||
Decrease/(Increase) of treasury share repurchase obligation under a share buy-back trading plan | 658 | -658 | 1 316 | ||||||||||
Dividends | -6 643 | -6 810 | 167 | ||||||||||
Net income of the period attributable to shareholders of Novartis AG | 17 783 | 10 210 | 7 573 | ||||||||||
Other comprehensive income attributable to shareholders of Novartis AG | -1 806 | -2 936 | 1 130 | ||||||||||
Balance at December 31 | 2 373.9 | 2 398.6 | -24.7 | 77 046 | 70 766 | 6 280 | |||||||
|
|||||||||||||
|
Pharmaceuticals | Alcon | Sandoz | Corporate (including eliminations) | Group | |||||||||||||||||
Q4 2015 USD m |
Q4 2014 USD m |
Q4 2015 USD m |
Q4 2014 USD m |
Q4 2015 USD m |
Q4 2014 USD m |
Q4 2015 USD m |
Q4 2014 USD m |
Q4 2015 USD m |
Q4 2014 USD m |
||||||||||||
Net sales to third parties from continuing operations | 7 865 | 7 860 | 2 349 | 2 703 | 2 306 | 2 512 | 12 520 | 13 075 | |||||||||||||
Sales to continuing and discontinued segments | 28 | 61 | 10 | 11 | 27 | 70 | -65 | -87 | 0 | 55 | |||||||||||
Net sales from continuing operations | 7 893 | 7 921 | 2 359 | 2 714 | 2 333 | 2 582 | -65 | -87 | 12 520 | 13 130 | |||||||||||
Other revenues | 224 | 171 | 4 | 10 | 7 | 3 | 49 | 40 | 284 | 224 | |||||||||||
Cost of goods sold | -2 035 | -1 709 | -1 250 | -1 320 | -1 367 | -1 527 | 103 | 140 | -4 549 | -4 416 | |||||||||||
Gross profit from continuing operations | 6 082 | 6 383 | 1 113 | 1 404 | 973 | 1 058 | 87 | 93 | 8 255 | 8 938 | |||||||||||
Marketing & Sales | -2 166 | -2 157 | -590 | -641 | -419 | -431 | -3 175 | -3 229 | |||||||||||||
Research & Development | -2 022 | -2 073 | -242 | -247 | -208 | -217 | -2 472 | -2 537 | |||||||||||||
General & Administration | -236 | -294 | -133 | -162 | -92 | -102 | -249 | -178 | -710 | -736 | |||||||||||
Other income | 258 | 215 | 10 | 42 | 62 | 37 | 266 | 312 | 596 | 606 | |||||||||||
Other expense | -445 | -463 | -26 | -31 | -100 | -55 | -246 | -142 | -817 | -691 | |||||||||||
Operating income from continuing operations | 1 471 | 1 611 | 132 | 365 | 216 | 290 | -142 | 85 | 1 677 | 2 351 | |||||||||||
as % of net sales | 18.7% | 20.5% | 5.6% | 13.5% | 9.4% | 11.5% | 13.4% | 18.0% | |||||||||||||
Income from associated companies | 1 | 1 | 9 | 579 | 10 | 580 | |||||||||||||||
Interest expense | -158 | -188 | |||||||||||||||||||
Other financial income and expense | -398 | 13 | |||||||||||||||||||
Income before taxes from continuing operations | 1 131 | 2 756 | |||||||||||||||||||
Taxes | -77 | -308 | |||||||||||||||||||
Net income from continuing operations | 1 054 | 2 448 | |||||||||||||||||||
Net income/loss from discontinued operations | 2 | -961 | |||||||||||||||||||
Net income | 1 056 | 1 487 | |||||||||||||||||||
Pharmaceuticals | Alcon | Sandoz | Corporate (including eliminations) | Group | |||||||||||||||||
FY 2015 USD m |
FY 2014 USD m |
FY 2015 USD m |
FY 2014 USD m |
FY 2015 USD m |
FY 2014 USD m |
FY 2015 USD m |
FY 2014 USD m |
FY 2015 USD m |
FY 2014 USD m |
||||||||||||
Net sales to third parties from continuing operations | 30 445 | 31 791 | 9 812 | 10 827 | 9 157 | 9 562 | 49 414 | 52 180 | |||||||||||||
Sales to continuing and discontinued segments | 137 | 262 | 45 | 49 | 128 | 286 | -284 | -358 | 26 | 239 | |||||||||||
Net sales from continuing operations | 30 582 | 32 053 | 9 857 | 10 876 | 9 285 | 9 848 | -284 | -358 | 49 440 | 52 419 | |||||||||||
Other revenues | 790 | 629 | 25 | 34 | 25 | 12 | 107 | 540 | 947 | 1 215 | |||||||||||
Cost of goods sold | -7 379 | -6 889 | -5 153 | -5 193 | -5 325 | -5 751 | 453 | 488 | -17 404 | -17 345 | |||||||||||
Gross profit from continuing operations | 23 993 | 25 793 | 4 729 | 5 717 | 3 985 | 4 109 | 276 | 670 | 32 983 | 36 289 | |||||||||||
Marketing & Sales | -7 789 | -8 178 | -2 398 | -2 474 | -1 585 | -1 725 | -11 772 | -12 377 | |||||||||||||
Research & Development | -7 232 | -7 331 | -926 | -928 | -777 | -827 | -8 935 | -9 086 | |||||||||||||
General & Administration | -937 | -1 009 | -544 | -613 | -346 | -376 | -648 | -618 | -2 475 | -2 616 | |||||||||||
Other income | 1 145 | 734 | 58 | 79 | 109 | 97 | 737 | 481 | 2 049 | 1 391 | |||||||||||
Other expense | -1 583 | -1 538 | -125 | -184 | -381 | -190 | -784 | -600 | -2 873 | -2 512 | |||||||||||
Operating income from continuing operations | 7 597 | 8 471 | 794 | 1 597 | 1 005 | 1 088 | -419 | -67 | 8 977 | 11 089 | |||||||||||
as % of net sales | 25.0% | 26.6% | 8.1% | 14.8% | 11.0% | 11.4% | 18.2% | 21.3% | |||||||||||||
Income from associated companies | 812 | 2 | 4 | 264 | 1 102 | 266 | 1 918 | ||||||||||||||
Interest expense | -655 | -704 | |||||||||||||||||||
Other financial income and expense | -454 | -31 | |||||||||||||||||||
Income before taxes from continuing operations | 8 134 | 12 272 | |||||||||||||||||||
Taxes | -1 106 | -1 545 | |||||||||||||||||||
Net income from continuing operations | 7 028 | 10 727 | |||||||||||||||||||
Net income/loss from discontinued operations | 10 766 | -447 | |||||||||||||||||||
Net income | 17 794 | 10 280 | |||||||||||||||||||
|
Q4 2015 USD m |
Q4 2014 USD m |
FY 2015 USD m |
FY 2014 USD m |
||||||
Net sales to third parties of discontinued operations | 1 558 | 601 | 5 816 | ||||||
Sales to continuing segments | 14 | 19 | 78 | ||||||
Net sales of discontinued operations | 1 572 | 620 | 5 894 | ||||||
Other revenues | 16 | 23 | 65 | ||||||
Cost of goods sold | -1 022 | -376 | -3 073 | ||||||
Gross profit of discontinued operations | 566 | 267 | 2 886 | ||||||
Marketing & Sales | -447 | -244 | -1 812 | ||||||
Research & Development | -216 | -181 | -857 | ||||||
General & Administration | -108 | -58 | -431 | ||||||
Other income | 5 | 91 | 13 420 | 1 007 | |||||
Other expense | -99 | -1 065 | -727 | -1 146 | |||||
Operating income/loss of discontinued operations | -94 | -1 179 | 12 477 | -353 | |||||
as % of net sales | nm | -75.7% | nm | -6.1% | |||||
Income from associated companies | -1 | 2 | 2 | ||||||
Income/loss before taxes of discontinued operations | -94 | -1 180 | 12 479 | -351 | |||||
Taxes | 96 | 219 | -1 713 | -96 | |||||
Income/loss of discontinued operations | 2 | -961 | 10 766 | -447 | |||||
nm = not meaningful |
Level 1 | Level 2 | Level 3 | Valued at amortized cost or cost | Total | |||||||||||||||||
Dec 31, 2015 USD m |
Dec 31, 2014 USD m |
Dec 31, 2015 USD m |
Dec 31, 2014 USD m |
Dec 31, 2015 USD m |
Dec 31, 2014 USD m |
Dec 31, 2015 USD m |
Dec 31, 2014 USD m |
Dec 31, 2015 USD m |
Dec 31, 2014 USD m |
||||||||||||
Debt securities | 316 | 301 | 23 | 26 | 339 | 327 | |||||||||||||||
Equity securities | 6 | 15 | 6 | 15 | |||||||||||||||||
Fund investments | 29 | 29 | 4 | 6 | 33 | 35 | |||||||||||||||
Total available-for-sale marketable securities | 351 | 345 | 23 | 26 | 4 | 6 | 378 | 377 | |||||||||||||
Time deposits with original maturity more than 90 days | 164 | 6 | 164 | 6 | |||||||||||||||||
Derivative financial instruments | 143 | 356 | 143 | 356 | |||||||||||||||||
Accrued interest on debt securities | 2 | 3 | 2 | 3 | |||||||||||||||||
Total marketable securities, time deposits and derivative financial instruments | 351 | 345 | 166 | 382 | 4 | 6 | 166 | 9 | 687 | 742 | |||||||||||
Financial investments and long-term loans | |||||||||||||||||||||
Available-for-sale financial investments | 700 | 605 | 473 | 332 | 1 173 | 937 | |||||||||||||||
Fund investments | 90 | 71 | 90 | 71 | |||||||||||||||||
Contingent consideration receivables | 550 | 550 | |||||||||||||||||||
Long-term loans and receivables from customers and finance lease, advances, security deposits | 653 | 712 | 653 | 712 | |||||||||||||||||
Financial investments and long-term loans | 700 | 605 | 1 113 | 403 | 653 | 712 | 2 466 | 1 720 | |||||||||||||
Associated companies at fair value through profit or loss | 66 | 181 | 168 | 181 | 234 | ||||||||||||||||
Total associated companies at fair value through profit or loss | 66 | 181 | 168 | 181 | 234 | ||||||||||||||||
Contingent consideration payables | -790 | -756 | -790 | -756 | |||||||||||||||||
Other financial liabilities | -315 | -315 | |||||||||||||||||||
Derivative financial instruments | -30 | -52 | -30 | -52 | |||||||||||||||||
Total financial liabilities at fair value | -30 | -52 | -1 105 | -756 | -1 135 | -808 | |||||||||||||||
Pharmaceuticals | Alcon | Sandoz | Corporate | Total Group | |||||||||||||||||
Q4 2015 USD m |
Q4 2014 USD m |
Q4 2015 USD m |
Q4 2014 USD m |
Q4 2015 USD m |
Q4 2014 USD m |
Q4 2015 USD m |
Q4 2014 USD m |
Q4 2015 USD m |
Q4 2014 USD m |
||||||||||||
IFRS Operating income from continuing operations | 1 471 | 1 611 | 132 | 365 | 216 | 290 | -142 | 85 | 1 677 | 2 351 | |||||||||||
Amortization of intangible assets | 369 | 67 | 510 | 522 | 89 | 96 | 1 | 968 | 686 | ||||||||||||
Impairments | |||||||||||||||||||||
Intangible assets
|
-14 | 155 | 1 | 15 | 12 | 2 | 167 | ||||||||||||||
Property, plant & equipment related to the Group-wide rationalization of manufacturing sites
|
5 | 2 | -1 | 5 | 1 | ||||||||||||||||
Other property, plant & equipment
|
3 | -6 | 1 | 13 | 5 | 15 | 1 | 32 | |||||||||||||
Financial assets
|
3 | 6 | 1 | 57 | 43 | 60 | 50 | ||||||||||||||
Total impairment charges | -3 | 157 | 2 | -1 | 28 | 18 | 72 | 44 | 99 | 218 | |||||||||||
Acquisition or divestment related items | |||||||||||||||||||||
- Income
|
-8 | -1 | -80 | -89 | |||||||||||||||||
- Expense
|
45 | 26 | 1 | 85 | 131 | 26 | |||||||||||||||
Total acquisition or divestment related items, net | 37 | 26 | 5 | 42 | 26 | ||||||||||||||||
Other exceptional items | |||||||||||||||||||||
Exceptional divestment gains
|
-145 | -34 | -54 | -248 | -199 | -282 | |||||||||||||||
Restructuring items
|
|||||||||||||||||||||
- Income
|
-15 | -13 | -3 | -11 | -4 | -22 | -24 | ||||||||||||||
- Expense
|
121 | 220 | 18 | 21 | 15 | 12 | 15 | 169 | 253 | ||||||||||||
Legal-related items
|
|||||||||||||||||||||
- Expense
|
165 | 34 | 30 | 199 | 30 | ||||||||||||||||
Additional exceptional income
|
-59 | -29 | -26 | -26 | -88 | ||||||||||||||||
Additional exceptional expense
|
105 | 2 | 11 | 28 | 15 | 19 | 29 | 150 | 59 | ||||||||||||
Total other exceptional items | 231 | 116 | 26 | 9 | 64 | 12 | -50 | -189 | 271 | -52 | |||||||||||
Total adjustments | 634 | 366 | 538 | 530 | 181 | 126 | 27 | -144 | 1 380 | 878 | |||||||||||
Core operating income from continuing operations | 2 105 | 1 977 | 670 | 895 | 397 | 416 | -115 | -59 | 3 057 | 3 229 | |||||||||||
as % of net sales | 26.8% | 25.2% | 28.5% | 33.1% | 17.2% | 16.6% | 24.4% | 24.7% | |||||||||||||
Income from associated companies | 1 | 1 | 9 | 579 | 10 | 580 | |||||||||||||||
Core adjustments to income from associated companies, net of tax | 233 | -370 | 233 | -370 | |||||||||||||||||
Interest expense | -158 | -188 | |||||||||||||||||||
Other financial income and expense1 | -32 | 13 | |||||||||||||||||||
Taxes (adjusted for above items) | -403 | -407 | |||||||||||||||||||
Core net income from continuing operations | 2 707 | 2 857 | |||||||||||||||||||
Core net loss/income from discontinued operations2 | -48 | 57 | |||||||||||||||||||
Core net income | 2 659 | 2 914 | |||||||||||||||||||
Core net income attributable to shareholders of Novartis AG | 2 657 | 2 918 | |||||||||||||||||||
Core EPS from continuing operations (USD)3 | 1.14 | 1.19 | |||||||||||||||||||
Core EPS from discontinued operations (USD)3 | -0.03 | 0.02 | |||||||||||||||||||
Core EPS (USD)3 | 1.11 | 1.21 | |||||||||||||||||||
1 Adjustments for charges of USD 0.3 billion are related to Venezuela subsidiaries.
|
|||||||||||||||||||||
2 For details on discontinued operations reconciliation from IFRS to core net income, please refer to page 67.
|
|||||||||||||||||||||
2 Earnings per share (EPS) is calculated on the amount of net income attributable to shareholders of Novartis AG.
|
Pharmaceuticals | Alcon | Sandoz | Corporate | Total Group | |||||||||||||||||
FY 2015 USD m |
FY 2014 USD m |
FY 2015 USD m |
FY 2014 USD m |
FY 2015 USD m |
FY 2014 USD m |
FY 2015 USD m |
FY 2014 USD m |
FY 2015 USD m |
FY 2014 USD m |
||||||||||||
IFRS Operating income from continuing operations | 7 597 | 8 471 | 794 | 1 597 | 1 005 | 1 088 | -419 | -67 | 8 977 | 11 089 | |||||||||||
Amortization of intangible assets | 1 290 | 276 | 2 063 | 2 064 | 356 | 400 | 3 | 3 709 | 2 743 | ||||||||||||
Impairments | |||||||||||||||||||||
Intangible assets
|
19 | 231 | 120 | 7 | 27 | 39 | 166 | 277 | |||||||||||||
Property, plant & equipment related to the Group-wide rationalization of manufacturing sites
|
6 | 23 | 83 | 89 | 23 | ||||||||||||||||
Other property, plant & equipment
|
-45 | -8 | 1 | -1 | 14 | 7 | 21 | 23 | -9 | 21 | |||||||||||
Financial assets
|
32 | 20 | 1 | 91 | 91 | 123 | 112 | ||||||||||||||
Total impairment charges | 12 | 266 | 121 | 6 | 124 | 47 | 112 | 114 | 369 | 433 | |||||||||||
Acquisition or divestment related items | |||||||||||||||||||||
- Income
|
-22 | -1 | -260 | -283 | |||||||||||||||||
- Expense
|
214 | 33 | 1 | 250 | 465 | 33 | |||||||||||||||
Total acquisition or divestment related items, net | 192 | 33 | -10 | 182 | 33 | ||||||||||||||||
Other exceptional items | |||||||||||||||||||||
Exceptional divestment gains
|
-626 | -237 | -54 | -294 | -680 | -531 | |||||||||||||||
Restructuring items
|
|||||||||||||||||||||
- Income
|
-27 | -56 | -7 | -24 | -3 | -5 | -39 | -83 | |||||||||||||
- Expense
|
391 | 632 | 60 | 95 | 121 | 21 | 57 | 1 | 629 | 749 | |||||||||||
Legal-related items
|
|||||||||||||||||||||
- Expense
|
578 | 125 | 4 | 40 | -30 | 30 | 592 | 155 | |||||||||||||
Additional exceptional income
|
-119 | -158 | -5 | -29 | -2 | -68 | -315 | -194 | -502 | ||||||||||||
Additional exceptional expense
|
132 | 162 | 33 | 102 | 15 | 18 | 65 | 105 | 245 | 387 | |||||||||||
Total other exceptional items | 329 | 468 | 85 | 144 | 174 | 36 | -35 | -473 | 553 | 175 | |||||||||||
Total adjustments | 1 823 | 1 043 | 2 269 | 2 214 | 654 | 483 | 67 | -356 | 4 813 | 3 384 | |||||||||||
Core operating income from continuing operations | 9 420 | 9 514 | 3 063 | 3 811 | 1 659 | 1 571 | -352 | -423 | 13 790 | 14 473 | |||||||||||
as % of net sales | 30.9% | 29.9% | 31.2% | 35.2% | 18.1% | 16.4% | 27.9% | 27.7% | |||||||||||||
Income from associated companies | 812 | 2 | 4 | 264 | 1 102 | 266 | 1 918 | ||||||||||||||
Core adjustments to income from associated companies, net of tax | -812 | 715 | -163 | 715 | -975 | ||||||||||||||||
Interest expense | -655 | -704 | |||||||||||||||||||
Other financial income and expense1 | -24 | -31 | |||||||||||||||||||
Taxes (adjusted for above items) | -2 051 | -2 028 | |||||||||||||||||||
Core net income from continuing operations | 12 041 | 12 653 | |||||||||||||||||||
Core net loss/income from discontinued operations2 | -256 | 102 | |||||||||||||||||||
Core net income | 11 785 | 12 755 | |||||||||||||||||||
Core net income attributable to shareholders of Novartis AG | 11 774 | 12 685 | |||||||||||||||||||
Core EPS from continuing operations (USD)3 | 5.01 | 5.19 | |||||||||||||||||||
Core EPS from discontinued operations (USD)3 | -0.11 | 0.04 | |||||||||||||||||||
Core EPS (USD)3 | 4.90 | 5.23 | |||||||||||||||||||
1 Adjustments for charges of USD 0.4 billion are related to Venezuela subsidiaries.
|
|||||||||||||||||||||
2 For details on discontinued operations reconciliation from IFRS to core net income, please refer to page 68.
|
|||||||||||||||||||||
2 Earnings per share (EPS) is calculated on the amount of net income attributable to shareholders of Novartis AG.
|
Q4 2015 IFRS results |
Amortization of intangible assets 1 |
Impairments 2 |
Acquisition or divestment related items, including restructuring and integration charges 3 |
Other exceptional items 4 |
Q4 2015 Core results |
Q4 2014 Core results |
|||||||||
USD millions | USD millions | USD millions | USD millions | USD millions | USD millions | USD millions | |||||||||
Gross profit from continuing operations | 8 255 | 957 | -5 | 57 | 9 264 | 9 601 | |||||||||
Operating income from continuing operations | 1 677 | 968 | 99 | 42 | 271 | 3 057 | 3 229 | ||||||||
Income before taxes from continuing operations | 1 131 | 1 072 | 99 | 42 | 766 | 3 110 | 3 264 | ||||||||
Taxes from continuing operations5 | -77 | -403 | -407 | ||||||||||||
Net income from continuing operations | 1 054 | 2 707 | 2 857 | ||||||||||||
Net loss/income from discontinued operations6 | 2 | -48 | 57 | ||||||||||||
Net income | 1 056 | 2 659 | 2 914 | ||||||||||||
EPS from continuing operations (USD)7 | 0.44 | 1.14 | 1.19 | ||||||||||||
EPS from discontinued operations (USD)7 | 0.00 | -0.03 | 0.02 | ||||||||||||
EPS (USD)7 | 0.44 | 1.11 | 1.21 | ||||||||||||
The following are adjustments to arrive at Core Gross Profit from continuing operations | |||||||||||||||
Cost of goods sold | -4 549 | 957 | -5 | 57 | -3 540 | -3 753 | |||||||||
The following are adjustments to arrive at Core Operating Income from continuing operations | |||||||||||||||
Marketing & Sales | -3 175 | 36 | -3 139 | -3 222 | |||||||||||
Research & Development | -2 472 | 11 | 7 | 76 | -2 378 | -2 315 | |||||||||
General & Administration | -710 | 36 | -674 | -713 | |||||||||||
Other income | 596 | -3 | -89 | -248 | 256 | 201 | |||||||||
Other expense | -817 | 100 | 131 | 314 | -272 | -323 | |||||||||
The following are adjustments to arrive at Core Income before taxes from continuing operations | |||||||||||||||
Income from associated companies | 10 | 104 | 129 | 243 | 210 | ||||||||||
Other financial income and expense | -398 | 366 | -32 | 13 | |||||||||||
1 Amortization of intangible assets: Cost of goods sold includes recurring amortization of acquired rights to in-market products and other production-related intangible assets; Research & Development includes the recurring amortization of acquired rights for technology platforms; Income from associated companies includes USD 104 million for the Novartis share of the estimated Roche core items.
|
|||||||||||||||
2 Impairments: Cost of goods sold, Research & Development and Other expense consist principally of net impairment charges or reversals related to intangible assets, property, plant and equipment, and financial assets; Other income includes a reversal of an impairment related to property, plant and equipment.
|
|||||||||||||||
3 Acquisition or divestment related items, including restructuring and integration charges: Other income and Other expense include items related to the portfolio transformation.
|
|||||||||||||||
4 Other exceptional items: Cost of goods sold and Other expense include charges for the Group-wide rationalization of manufacturing sites; Cost of goods sold also includes an inventory write-off; Marketing & Sales, Research & Development and Other expense include other restructuring charges; General & Administration includes charges for transforming IT and finance processes and expenses related to setup costs for Novartis Business Services; Other income includes additional gains from product divestments and items related to portfolio transformation; Other expense also includes legal settlement provisions; Income from associated companies includes USD 129 million for the Novartis share of the estimated OTC joint venture core items; Other financial income and expense includes a charge of USD 346 million related to Venezuela consisting of foreign exchange losses (USD 211 million), the loss on the sale of PDVSA bonds (USD 127 million) and the monetary loss due to hyperinflation (USD 8 million).
|
|||||||||||||||
5 Taxes on the adjustments between IFRS and core results take into account, for each individual item included in the adjustment, the tax rate that will finally be applicable to the item based on the jurisdiction where the adjustment will finally have a tax impact. Generally, this results in amortization and impairment of intangible assets and acquisition-related restructuring and integration items having a full tax impact. There is usually a tax impact on exceptional items although this is not always the case for items arising from legal settlements in certain jurisdictions. Adjustments related to income from associated companies are recorded net of any related tax effect. Due to these factors and the differing effective tax rates in the various jurisdictions, the tax on the total adjustments for continuing operations of USD 2.0 billion to arrive at the core results before tax amounts to USD 326 million. The average tax rate on the adjustments for continuing operations is 16.5%.
|
|||||||||||||||
6 For details on discontinued operations reconciliation from IFRS to core net income, please refer to page 67.
|
|||||||||||||||
7 Earnings per share (EPS) is calculated on the amount of net income attributable to shareholders of Novartis AG.
|
FY 2015 IFRS results |
Amortization of intangible assets 1 |
Impairments 2 |
Acquisition or divestment related items, including restructuring and integration charges 3 |
Other exceptional items 4 |
FY 2015 Core results |
FY 2014 Core results |
|||||||||
USD millions | USD millions | USD millions | USD millions | USD millions | USD millions | USD millions | |||||||||
Gross profit from continuing operations | 32 983 | 3 666 | 126 | 125 | 36 900 | 38 821 | |||||||||
Operating income from continuing operations | 8 977 | 3 709 | 369 | 182 | 553 | 13 790 | 14 473 | ||||||||
Income before taxes from continuing operations | 8 134 | 4 132 | 369 | 182 | 1 275 | 14 092 | 14 681 | ||||||||
Taxes from continuing operations5 | -1 106 | -2 051 | -2 028 | ||||||||||||
Net income from continuing operations | 7 028 | 12 041 | 12 653 | ||||||||||||
Net income/loss from discontinued operations6 | 10 766 | -256 | 102 | ||||||||||||
Net income | 17 794 | 11 785 | 12 755 | ||||||||||||
EPS from continuing operations (USD)7 | 2.92 | 5.01 | 5.19 | ||||||||||||
EPS from discontinued operations (USD)7 | 4.48 | -0.11 | 0.04 | ||||||||||||
EPS (USD)7 | 7.40 | 4.90 | 5.23 | ||||||||||||
The following are adjustments to arrive at Core Gross Profit from continuing operations | |||||||||||||||
Other revenues | 947 | -28 | 919 | 913 | |||||||||||
Cost of goods sold | -17 404 | 3 666 | 126 | 153 | -13 459 | -14 511 | |||||||||
The following are adjustments to arrive at Core Operating Income from continuing operations | |||||||||||||||
Marketing & Sales | -11 772 | 43 | -11 729 | -12 355 | |||||||||||
Research & Development | -8 935 | 43 | 40 | 114 | -8 738 | -8 723 | |||||||||
General & Administration | -2 475 | 86 | -2 389 | -2 552 | |||||||||||
Other income | 2 049 | -56 | -283 | -887 | 823 | 563 | |||||||||
Other expense | -2 873 | 259 | 465 | 1 072 | -1 077 | -1 281 | |||||||||
The following are adjustments to arrive at Core Income before taxes from continuing operations | |||||||||||||||
Income from associated companies | 266 | 423 | 292 | 981 | 943 | ||||||||||
Other financial income and expense | -454 | 430 | -24 | -31 | |||||||||||
1 Amortization of intangible assets: Cost of goods sold includes recurring amortization of acquired rights to in-market products and other production-related intangible assets; Research & Development includes the recurring amortization of acquired rights for technology platforms; Income from associated companies includes USD 423 million for the Novartis share of the estimated Roche core items.
|
|||||||||||||||
2 Impairments: Cost of goods sold, Research & Development and Other expense consist principally of net impairment charges or reversals related to intangible assets, property, plant and equipment, and financial assets; Other income includes a reversal of an impairment related to property, plant and equipment.
|
|||||||||||||||
3 Acquisition or divestment related items, including restructuring and integration charges: Other income and Other expense include items related to the portfolio transformation.
|
|||||||||||||||
4 Other exceptional items: Other revenues and Other income include additional gains from product divestments; Cost of goods sold and Other expense include charges for the Group-wide rationalization of manufacturing sites; Cost of goods sold also includes an inventory write-off; Marketing & Sales, Research & Development and Other expense include other restructuring charges; Research & Development also includes expenses related to product acquisitions; General & Administration includes charges for transforming IT and finance processes and expenses related to setup costs for Novartis Business Services; Other income also includes a gain of USD 110 million from a Swiss pension plan amendment and items related to portfolio transformation; Other expense also includes legal settlement provisions; Income from associated companies includes USD 292 million for the Novartis share of the estimated OTC joint venture core items; Other financial income and expense includes a charge of USD 410 million related to Venezuela consisting of foreign exchange losses (USD 211 million), the loss on the sale of PDVSA bonds (USD 127 million) and the monetary loss due to hyperinflation (USD 72 million).
|
|||||||||||||||
5 Taxes on the adjustments between IFRS and core results take into account, for each individual item included in the adjustment, the tax rate that will finally be applicable to the item based on the jurisdiction where the adjustment will finally have a tax impact. Generally, this results in amortization and impairment of intangible assets and acquisition-related restructuring and integration items having a full tax impact. There is usually a tax impact on exceptional items although this is not always the case for items arising from legal settlements in certain jurisdictions. Adjustments related to income from associated companies are recorded net of any related tax effect. Due to these factors and the differing effective tax rates in the various jurisdictions, the tax on the total adjustments for continuing operations of USD 6.0 billion to arrive at the core results before tax amounts to USD 945 million. The average tax rate on the adjustments for continuing operations is 15.9%.
|
|||||||||||||||
6 For details on discontinued operations reconciliation from IFRS to core net income, please refer to page 68.
|
|||||||||||||||
7 Earnings per share (EPS) is calculated on the amount of net income attributable to shareholders of Novartis AG.
|
Q4 2015 IFRS results |
Amortization of intangible assets 1 |
Impairments 2 |
Acquisition or divestment related items, including restructuring and integration charges 3 |
Other exceptional items 4 |
Q4 2015 Core results |
Q4 2014 Core results |
|||||||||
USD millions | USD millions | USD millions | USD millions | USD millions | USD millions | USD millions | |||||||||
Gross profit | 6 082 | 362 | -20 | 34 | 6 458 | 6 415 | |||||||||
Operating income | 1 471 | 369 | -3 | 37 | 231 | 2 105 | 1 977 | ||||||||
The following are adjustments to arrive at Core Gross Profit | |||||||||||||||
Cost of goods sold | -2 035 | 362 | -20 | 34 | -1 659 | -1 677 | |||||||||
The following are adjustments to arrive at Core Operating Income | |||||||||||||||
Marketing & Sales | -2 166 | 36 | -2 130 | -2 155 | |||||||||||
Research & Development | -2 022 | 7 | 6 | 74 | -1 935 | -1 868 | |||||||||
Other income | 258 | -3 | -8 | -161 | 86 | 97 | |||||||||
Other expense | -445 | 14 | 45 | 248 | -138 | -218 | |||||||||
1 Amortization of intangible assets: Cost of goods sold includes recurring amortization of acquired rights to in-market products and other production-related intangible assets; Research & Development includes the recurring amortization of acquired rights for technology platforms.
|
|||||||||||||||
2 Impairments: Cost of goods sold and Other income include a reversal of intangible asset impairments; Research & Development includes impairment charges for in process projects and termination of collaboration and license agreements; Other income includes a reversal of an intangible asset impairment; Other expense includes impairment charges related to property, plant and equipment and financial assets.
|
|||||||||||||||
3 Acquisition or divestment related items, including restructuring and integration charges: Other income and Other expense include income and costs related to the portfolio transformation.
|
|||||||||||||||
4 Other exceptional items: Cost of goods sold and Other expense include net restructuring charges related to the Group-wide rationalization of manufacturing sites; Cost of goods sold also includes an inventory write-off; Marketing & Sales, Research & Development and Other expense include other restructuring charges; Research & Development also includes expenses related to product acquisitions; Other income includes additional gains from product divestments; Other expense also includes legal settlement provisions.
|
FY 2015 IFRS results |
Amortization of intangible assets 1 |
Impairments 2 |
Acquisition or divestment related items, including restructuring and integration charges 3 |
Other exceptional items 4 |
FY 2015 Core results |
FY 2014 Core results |
|||||||||
USD millions | USD millions | USD millions | USD millions | USD millions | USD millions | USD millions | |||||||||
Gross profit | 23 993 | 1 262 | -20 | 88 | 25 323 | 26 100 | |||||||||
Operating income | 7 597 | 1 290 | 12 | 192 | 329 | 9 420 | 9 514 | ||||||||
The following are adjustments to arrive at Core Gross Profit | |||||||||||||||
Other revenues | 790 | -28 | 762 | 629 | |||||||||||
Cost of goods sold | -7 379 | 1 262 | -20 | 116 | -6 021 | -6 582 | |||||||||
The following are adjustments to arrive at Core Operating Income | |||||||||||||||
Marketing & Sales | -7 789 | 43 | -7 746 | -8 176 | |||||||||||
Research & Development | -7 232 | 28 | 39 | 112 | -7 053 | -6 997 | |||||||||
Other income | 1 145 | -56 | -22 | -743 | 324 | 270 | |||||||||
Other expense | -1 583 | 49 | 214 | 829 | -491 | -675 | |||||||||
1 Amortization of intangible assets: Cost of goods sold includes recurring amortization of acquired rights to in-market products and other production-related intangible assets; Research & Development includes the recurring amortization of acquired rights for technology platforms.
|
|||||||||||||||
2 Impairments: Cost of goods sold and Other income include a reversal of intangible asset impairments; Research & Development includes impairment charges for in process projects and termination of collaboration and license agreements; Other expense includes impairment charges related to property, plant and equipment and financial assets.
|
|||||||||||||||
3 Acquisition or divestment related items, including restructuring and integration charges: Other income and Other expense include income and costs related to the portfolio transformation.
|
|||||||||||||||
4 Other exceptional items: Other revenues and Other income include additional gains from product divestments; Cost of goods sold and Other expense include net restructuring charges related to the Group-wide rationalization of manufacturing sites; Cost of goods sold also includes an inventory write-off; Marketing & Sales, Research & Development and Other expense include other restructuring charges; Research & Development also includes expenses related to product acquisitions; Other income also includes a gain from a Swiss pension plan amendment; Other expense also includes legal settlement provisions.
|
|||||||||||||||
|
Q4 2015 IFRS results |
Amortization of intangible assets 1 |
Impairments 2 |
Acquisition or divestment related items, including restructuring and integration charges |
Other exceptional items 3 |
Q4 2015 Core results |
Q4 2014 Core results |
|||||||||
USD millions | USD millions | USD millions | USD millions | USD millions | USD millions | USD millions | |||||||||
Gross profit | 1 113 | 507 | 2 | 1 622 | 1 924 | ||||||||||
Operating income | 132 | 510 | 2 | 26 | 670 | 895 | |||||||||
The following are adjustments to arrive at Core Gross Profit | |||||||||||||||
Cost of goods sold | -1 250 | 507 | 2 | -741 | -800 | ||||||||||
The following are adjustments to arrive at Core Operating Income | |||||||||||||||
Research & Development | -242 | 3 | 1 | 2 | -236 | -232 | |||||||||
General & Administration | -133 | 10 | -123 | -148 | |||||||||||
Other income | 10 | -4 | 6 | 3 | |||||||||||
Other expense | -26 | 1 | 16 | -9 | -16 | ||||||||||
1 Amortization of intangible assets: Cost of goods sold includes recurring amortization of acquired rights to in-market products and other production-related intangible assets; Research & Development includes the recurring amortization of acquired rights for technology platforms.
|
|||||||||||||||
2 Impairments: Research & Development and Other expense include impairment charges related to property, plant and equipment.
|
|||||||||||||||
3 Other exceptional items: Cost of goods sold includes net restructuring charges related to the Group-wide rationalization of manufacturing sites; Research & Development includes non capitalized costs for the US; General & Administration includes charges for transforming IT and finance processes; Other income includes a partial reversal of restructuring charges; Other expense includes other restructuring charges.
|
|||||||||||||||
|
|||||||||||||||
|
FY 2015 IFRS results |
Amortization of intangible assets 1 |
Impairments 2 |
Acquisition or divestment related items, including restructuring and integration charges |
Other exceptional items 3 |
FY 2015 Core results |
FY 2014 Core results |
|||||||||
USD millions | USD millions | USD millions | USD millions | USD millions | USD millions | USD millions | |||||||||
Gross profit | 4 729 | 2 049 | 119 | 4 | 6 901 | 7 799 | |||||||||
Operating income | 794 | 2 063 | 121 | 85 | 3 063 | 3 811 | |||||||||
The following are adjustments to arrive at Core Gross Profit | |||||||||||||||
Cost of goods sold | -5 153 | 2 049 | 119 | 4 | -2 981 | -3 111 | |||||||||
The following are adjustments to arrive at Core Operating Income | |||||||||||||||
Research & Development | -926 | 14 | 1 | 2 | -909 | -903 | |||||||||
General & Administration | -544 | 32 | -512 | -568 | |||||||||||
Other income | 58 | -13 | 45 | 26 | |||||||||||
Other expense | -125 | 1 | 60 | -64 | -89 | ||||||||||
1 Amortization of intangible assets: Cost of goods sold includes recurring amortization of acquired rights to in-market products and other production-related intangible assets; Research & Development includes the recurring amortization of acquired rights for technology platforms.
|
|||||||||||||||
2 Impairments: Cost of goods sold includes impairment charges related to intangible assets; Research & Development and Other expense include impairment charges related to property, plant and equipment.
|
|||||||||||||||
3 Other exceptional items: Cost of goods sold includes net restructuring charges related to the Group-wide rationalization of manufacturing sites; Research & Development includes non capitalized costs for the US; General & Administration includes charges for transforming IT and finance processes; Other income includes a gain from a Swiss pension plan amendment and a partial reversal of restructuring charges; Other expense includes other restructuring charges and a legal settlement.
|
|||||||||||||||
|
Q4 2015 IFRS results |
Amortization of intangible assets 1 |
Impairments 2 |
Acquisition or divestment related items, including restructuring and integration charges 3 |
Other exceptional items 4 |
Q4 2015 Core results |
Q4 2014 Core results |
|||||||||
USD millions | USD millions | USD millions | USD millions | USD millions | USD millions | USD millions | |||||||||
Gross profit | 973 | 88 | 15 | 21 | 1 097 | 1 169 | |||||||||
Operating income | 216 | 89 | 28 | 64 | 397 | 416 | |||||||||
The following are adjustments to arrive at Core Gross Profit | |||||||||||||||
Cost of goods sold | -1 367 | 88 | 15 | 21 | -1 243 | -1 416 | |||||||||
The following are adjustments to arrive at Core Operating Income | |||||||||||||||
Research & Development | -208 | 1 | -207 | -215 | |||||||||||
Other income | 62 | -1 | 61 | 37 | |||||||||||
Other expense | -100 | 13 | 1 | 43 | -43 | -42 | |||||||||
1 Amortization of intangible assets: Cost of goods sold includes recurring amortization of acquired rights to in-market products and other production-related intangible assets.
|
|||||||||||||||
2 Impairments: Cost of goods sold includes impairments of intangible assets; Other expense includes impairment charges related to property, plant and equipment.
|
|||||||||||||||
3 Acquisition or divestment related items, including restructuring and integration charges: Other income and Other expense include items related to the portfolio transformation.
|
|||||||||||||||
4 Other exceptional items: Cost of goods sold includes marketable intangible assets not capitalized; Cost of goods sold and Other expense include net restructuring charges related to the Group-wide rationalization of manufacturing sites; Other expense also includes a legal settlement.
|
|||||||||||||||
|
FY 2015 IFRS results |
Amortization of intangible assets 1 |
Impairments 2 |
Acquisition or divestment related items, including restructuring and integration charges 3 |
Other exceptional items 4 |
FY 2015 Core results |
FY 2014 Core results |
|||||||||
USD millions | USD millions | USD millions | USD millions | USD millions | USD millions | USD millions | |||||||||
Gross profit | 3 985 | 355 | 27 | 33 | 4 400 | 4 554 | |||||||||
Operating income | 1 005 | 356 | 124 | 174 | 1 659 | 1 571 | |||||||||
The following are adjustments to arrive at Core Gross Profit | |||||||||||||||
Cost of goods sold | -5 325 | 355 | 27 | 33 | -4 910 | -5 306 | |||||||||
The following are adjustments to arrive at Core Operating Income | |||||||||||||||
Research & Development | -777 | 1 | -776 | -823 | |||||||||||
Other income | 109 | -1 | -4 | 104 | 93 | ||||||||||
Other expense | -381 | 97 | 1 | 145 | -138 | -152 | |||||||||
1 Amortization of intangible assets: Cost of goods sold includes recurring amortization of acquired rights to in-market products and other production-related intangible assets.
|
|||||||||||||||
2 Impairments: Cost of goods sold includes impairments of intangible assets; Other expense includes impairment charges related to property, plant and equipment.
|
|||||||||||||||
3 Acquisition or divestment related items, including restructuring and integration charges: Other income and Other expense include items related to the portfolio transformation.
|
|||||||||||||||
4 Other exceptional items: Cost of goods sold includes marketable intangible assets not capitalized; Cost of goods sold and Other expense include net restructuring charges related to the Group-wide rationalization of manufacturing sites; Other income includes a gain from a Swiss pension plan amendment; Other expense also includes a legal settlement.
|
|||||||||||||||
|
Q4 2015 IFRS results |
Amortization of intangible assets |
Impairments 1 |
Acquisition or divestment related items, including restructuring and integration charges 2 |
Other exceptional items 3 |
Q4 2015 Core results |
Q4 2014 Core results |
|||||||||
USD millions | USD millions | USD millions | USD millions | USD millions | USD millions | USD millions | |||||||||
Gross profit | 87 | 87 | 93 | ||||||||||||
Operating loss | -142 | 72 | 5 | -50 | -115 | -59 | |||||||||
The following are adjustments to arrive at Core Operating Loss | |||||||||||||||
General & Administration | -249 | 26 | -223 | -169 | |||||||||||
Other income | 266 | -80 | -83 | 103 | 64 | ||||||||||
Other expense | -246 | 72 | 85 | 7 | -82 | -47 | |||||||||
1 Impairments: Other expense includes impairment charges related to property, plant and equipment and financial assets.
|
|||||||||||||||
2 Acquisition or divestment related items, including restructuring and integration charges: Other income and Other expense include items related to the portfolio transformation.
|
|||||||||||||||
3 Other exceptional items: General & Administration and Other expense include expenses related to setup costs for Novartis Business Services; Other income includes a reversal of a provision and items related to portfolio transformation.
|
FY 2015 IFRS results |
Amortization of intangible assets |
Impairments 1 |
Acquisition or divestment related items, including restructuring and integration charges 2 |
Other exceptional items 3 |
FY 2015 Core results |
FY 2014 Core results |
|||||||||
USD millions | USD millions | USD millions | USD millions | USD millions | USD millions | USD millions | |||||||||
Gross profit | 276 | 276 | 368 | ||||||||||||
Operating loss | -419 | 112 | -10 | -35 | -352 | -423 | |||||||||
The following are adjustments to arrive at Core Operating Loss | |||||||||||||||
General & Administration | -648 | 54 | -594 | -600 | |||||||||||
Other income | 737 | -260 | -127 | 350 | 174 | ||||||||||
Other expense | -784 | 112 | 250 | 38 | -384 | -365 | |||||||||
1 Impairments: Other expense includes impairment charges related to property, plant and equipment and financial assets.
|
|||||||||||||||
2 Acquisition or divestment related items, including restructuring and integration charges: Other income and Other expense include items related to the portfolio transformation.
|
|||||||||||||||
3 Other exceptional items: General & Administration and Other expense include expenses related to setup costs for Novartis Business Services; Other income includes a gain from a Swiss pension plan amendment, a reversal of a provision and items related to portfolio transformation; Other expense also includes a credit for a legal settlement charged to the divisions.
|
|||||||||||||||
|
Q4 2015 IFRS results |
Amortization of intangible assets |
Impairments |
Acquisition or divestment related items, including restructuring and integration charges 1 |
Other exceptional items 2 |
Q4 2015 Core results |
Q4 2014 Core results |
|||||||||
USD millions | USD millions | USD millions | USD millions | USD millions | USD millions | USD millions | |||||||||
Gross profit | 876 | ||||||||||||||
Operating loss/income | -94 | 90 | 2 | -2 | 93 | ||||||||||
Loss/income before taxes | -94 | 90 | 2 | -2 | 92 | ||||||||||
Taxes3 | 96 | -46 | -35 | ||||||||||||
Net income/loss | 2 | -48 | 57 | ||||||||||||
EPS (USD)4 | -0.03 | 0.02 | |||||||||||||
The following are adjustments to arrive at Core Operating Loss | |||||||||||||||
Other income | 5 | -1 | 4 | 15 | |||||||||||
Other expense | -99 | 90 | 3 | -6 | -27 | ||||||||||
1 Acquisition or divestment related items, including restructuring and integration charges: Other income and Other expense include items related to the portfolio transformation.
|
|||||||||||||||
2 Other exceptional items: Other income and Other expense include restructuring charges.
|
|||||||||||||||
3 Taxes on the adjustments between IFRS and core results take into account, for each individual item included in the adjustment, the tax rate that will finally be applicable to the item based on the jurisdiction where the adjustment will finally have a tax impact. There is usually a tax impact on exceptional items although this is not always the case for items arising from legal settlements in certain jurisdictions.
|
|||||||||||||||
4 Earnings per share (EPS) is calculated on the amount of net income attributable to shareholders of Novartis AG.
|
FY 2015 IFRS results |
Amortization of intangible assets |
Impairments 1 |
Acquisition or divestment related items, including restructuring and integration charges 2 |
Other exceptional items 3 |
FY 2015 Core results |
FY 2014 Core results |
|||||||||
USD millions | USD millions | USD millions | USD millions | USD millions | USD millions | USD millions | |||||||||
Gross profit | 267 | 6 | 273 | 3 272 | |||||||||||
Operating income/loss | 12 477 | -83 | -12 627 | 8 | -225 | 143 | |||||||||
Income/loss before taxes | 12 479 | -83 | -12 627 | 8 | -223 | 145 | |||||||||
Taxes4 | -1 713 | -33 | -43 | ||||||||||||
Net income/loss | 10 766 | -256 | 102 | ||||||||||||
EPS (USD)5 | 4.48 | -0.11 | 0.04 | ||||||||||||
The following are adjustments to arrive at Core Gross Profit | |||||||||||||||
Cost of goods sold | -376 | 6 | -370 | -2 687 | |||||||||||
The following are adjustments to arrive at Core Operating Loss | |||||||||||||||
Other income | 13 420 | -13 310 | -1 | 109 | 41 | ||||||||||
Other expense | -727 | -83 | 683 | 3 | -124 | -78 | |||||||||
1 Impairments: Other expense includes the partial reversal of the influenza Vaccines business impairment charge recorded in 2014.
|
|||||||||||||||
2 Acquisition or divestment related items, including restructuring and integration charges: Other income includes gains from the divestment of Animal Health (USD 4.6 billion) and from the transactions with GSK (USD 2.8 billion for the non-influenza Vaccines business and USD 5.9 billion resulting from the contribution of the former Novartis OTC division into the GSK consumer healthcare joint venture in exchange for 36.5% interest in this newly created entity); Other expense includes additional transaction related expenses of USD 0.6 billion and other portfolio transformation related costs.
|
|||||||||||||||
3 Other exceptional items: Cost of goods sold, Other income and Other expense include restructuring charges.
|
|||||||||||||||
4 Taxes on the adjustments between IFRS and core results take into account, for each individual item included in the adjustment, the tax rate that will finally be applicable to the item based on the jurisdiction where the adjustment will finally have a tax impact. There is usually a tax impact on exceptional items although this is not always the case for items arising from legal settlements in certain jurisdictions. Due to these factors and the differing effective tax rates in the various jurisdictions, the tax on the total adjustments of USD 12.7 billion to arrive at the core results before tax amounts to USD 1.7 billion. The average tax rate on the adjustments is 13.2%.
|
|||||||||||||||
5 Earnings per share (EPS) is calculated on the amount of net income attributable to shareholders of Novartis AG.
|
|||||||||||||||
|
Q4 2015 USD m |
Q4 2014 USD m |
||||
Change in cash and cash equivalents | -654 | 3 382 | |||
Change in marketable securities, commodities, financial debt and financial derivatives | 807 | -751 | |||
Reduction in net debt | 153 | 2 631 | |||
Net debt at October 1 | -16 637 | -9 180 | |||
Net debt at December 31 | -16 484 | -6 549 | |||
FY 2015 USD m |
FY 2014 USD m |
||||
Change in cash and cash equivalents | -8 349 | 6 336 | |||
Change in marketable securities, commodities, financial debt and financial derivatives | -1 586 | -4 089 | |||
Increase/reduction in net debt | -9 935 | 2 247 | |||
Net debt at January 1 | -6 549 | -8 796 | |||
Net debt at December 31 | -16 484 | -6 549 | |||
Dec 31, 2015 USD m |
Dec 31, 2014 USD m |
||||
Current financial debts and derivative financial instruments | -5 604 | -6 612 | |||
Non-current financial debts | -16 327 | -13 799 | |||
Less liquidity: | |||||
Cash and cash equivalents | 4 674 | 13 023 | |||
Marketable securities, commodities and derivative financial instruments | 773 | 839 | |||
Net debt at December 31 | -16 484 | -6 549 | |||
Dec 31, 2015 |
Dec 31, 2014 |
||||
Number of shares outstanding | 2 373 894 817 | 2 398 626 257 | |||
Registered share price (CHF) | 86.80 | 92.35 | |||
ADR price (USD) | 86.04 | 92.66 | |||
Market capitalization (USD billions) | 208.3 | 223.7 | |||
Market capitalization (CHF billions) | 206.1 | 221.5 | |||
Q4 2015 USD m |
Q4 2014 USD m |
Change USD m |
|||||
Operating income from continuing operations | 1 677 | 2 351 | -674 | ||||
Reversal of non-cash items | |||||||
Depreciation, amortization and impairments
|
1 429 | 1 291 | 138 | ||||
Change in provisions and other non-current liabilities
|
518 | 316 | 202 | ||||
Other
|
-70 | -118 | 48 | ||||
Operating income adjusted for non-cash items | 3 554 | 3 840 | -286 | ||||
Interest and other financial receipts | 73 | 394 | -321 | ||||
Interest and other financial payments | -150 | -168 | 18 | ||||
Taxes paid | -528 | -559 | 31 | ||||
Payments out of provisions and other net cash movements in non-current liabilities | -291 | -251 | -40 | ||||
Change in inventory and trade receivables less trade payables | 1 190 | 1 422 | -232 | ||||
Change in other net current assets and other operating cash flow items | 249 | 45 | 204 | ||||
Cash flows from operating activities from continuing operations | 4 097 | 4 723 | -626 | ||||
Purchase of property, plant & equipment | -753 | -830 | 77 | ||||
Purchase of intangible, financial and other non-current assets | -561 | -304 | -257 | ||||
Proceeds from sales of property, plant & equipment, intangible, financial and other non-current assets | 159 | 366 | -207 | ||||
Free cash flow from continuing operations | 2 942 | 3 955 | -1 013 | ||||
Free cash flow from discontinued operations | 60 | 464 | -404 | ||||
Total free cash flow | 3 002 | 4 419 | -1 417 | ||||
FY 2015 USD m |
FY 2014 USD m |
Change USD m |
|||||
Operating income from continuing operations | 8 977 | 11 089 | -2 112 | ||||
Reversal of non-cash items | |||||||
Depreciation, amortization and impairments
|
5 575 | 4 751 | 824 | ||||
Change in provisions and other non-current liabilities
|
1 642 | 1 490 | 152 | ||||
Other
|
-96 | 122 | -218 | ||||
Operating income adjusted for non-cash items | 16 098 | 17 452 | -1 354 | ||||
Interest and other financial receipts | 1 180 | 1 067 | 113 | ||||
Interest and other financial payments | -669 | -692 | 23 | ||||
Taxes paid | -2 454 | -2 179 | -275 | ||||
Payments out of provisions and other net cash movements in non-current liabilities | -1 207 | -1 125 | -82 | ||||
Change in inventory and trade receivables less trade payables | -617 | -731 | 114 | ||||
Change in other net current assets and other operating cash flow items | -246 | 106 | -352 | ||||
Cash flows from operating activities from continuing operations | 12 085 | 13 898 | -1 813 | ||||
Purchase of property, plant & equipment | -2 367 | -2 624 | 257 | ||||
Purchase of intangible, financial and other non-current assets | -1 484 | -1 079 | -405 | ||||
Proceeds from sales of property, plant & equipment, intangible, financial and other non-current assets | 1 025 | 739 | 286 | ||||
Free cash flow from continuing operations | 9 259 | 10 934 | -1 675 | ||||
Free cash flow from discontinued operations | -230 | -172 | -58 | ||||
Total free cash flow | 9 029 | 10 762 | -1 733 | ||||
US | Rest of world | Total | |||||||||||||||||
Brands |
Business Franchise |
Indication |
USD m |
% change in constant currencies |
USD m |
% change in constant currencies |
USD m |
% change in USD |
% change in constant currencies |
||||||||||
Gleevec/Glivec | Oncology | Chronic myeloid leukemia and GIST | 677 | 8 | 542 | -1 | 1 219 | -1 | 4 | ||||||||||
Gilenya | Neuroscience | Relapsing multiple sclerosis | 413 | 27 | 329 | 10 | 742 | 11 | 18 | ||||||||||
Lucentis | Retina | Age-related macular degeneration | 499 | -4 | 499 | -15 | -4 | ||||||||||||
Tasigna | Oncology | Chronic myeloid leukemia | 165 | 9 | 267 | 8 | 432 | 1 | 8 | ||||||||||
Sandostatin | Oncology | Carcinoid tumors and Acromegaly | 205 | 4 | 208 | 10 | 413 | -1 | 7 | ||||||||||
Afinitor/Votubia | Oncology | Breast cancer / TSC | 198 | -12 | 184 | 5 | 382 | -10 | -4 | ||||||||||
Diovan/Co–Diovan | Established Medicines | Hypertension | 46 | -45 | 246 | -8 | 292 | -23 | -16 | ||||||||||
Galvus | Cardio-Metabolic | Diabetes | 294 | 12 | 294 | 0 | 12 | ||||||||||||
Exforge | Established Medicines | Hypertension | 9 | -55 | 240 | -3 | 249 | -16 | -7 | ||||||||||
Exjade | Oncology | Chronic iron overload | 97 | 20 | 151 | 4 | 248 | 2 | 9 | ||||||||||
Xolair1 | Respiratory | Asthma | 197 | 12 | 197 | -2 | 12 | ||||||||||||
Exelon/Exelon Patch | Neuroscience | Alzheimer's disease | 43 | -64 | 92 | -10 | 135 | -44 | -37 | ||||||||||
Neoral/Sandimmun(e) | Immunology and Dermatology | Transplantation | 12 | -14 | 132 | -3 | 144 | -12 | -3 | ||||||||||
Votrient | Oncology | Renal cell carcinoma | 87 | nm | 89 | nm | 176 | nm | nm | ||||||||||
Voltaren (excl. other divisions) | Established Medicines | Inflammation/pain | 140 | -9 | 140 | -19 | -9 | ||||||||||||
Tafinlar/Mekinist | Oncology | Melanoma | 79 | nm | 68 | nm | 147 | nm | nm | ||||||||||
Myfortic | Immunology and Dermatology | Transplantation | 30 | -12 | 85 | 5 | 115 | -12 | 0 | ||||||||||
Jakavi | Oncology | Myelofibrosis | 119 | 59 | 119 | 42 | 59 | ||||||||||||
Promacta/Revolade | Oncology | Immune thrombocytopenic purpura | 63 | nm | 70 | nm | 133 | nm | nm | ||||||||||
Ritalin/Focalin | Established Medicines | Attention deficit/ hyperactivity disorder | 44 | -49 | 36 | 0 | 80 | -38 | -32 | ||||||||||
Top 20 products total | 2 168 | 11 | 3 988 | 9 | 6 156 | 1 | 9 | ||||||||||||
Rest of portfolio | 475 | 15 | 1 234 | 6 | 1 709 | -3 | 8 | ||||||||||||
Total Division sales | 2 643 | 11 | 5 222 | 8 | 7 865 | 0 | 9 | ||||||||||||
|
|||||||||||||||||||
1 Net sales reflect Xolair sales for all indications (e.g. including Xolair SAA and Xolair CSU, which are managed by the Immunology and Dermatology).
|
|||||||||||||||||||
nm = not meaningful |
US | Rest of world | Total | |||||||||||||||||
Brands |
Business Franchise |
Indication |
USD m |
% change in constant currencies |
USD m |
% change in constant currencies |
USD m |
% change in USD |
% change in constant currencies |
||||||||||
Gleevec/Glivec | Oncology | Chronic myeloid leukemia and GIST | 2 533 | 17 | 2 125 | -5 | 4 658 | -2 | 5 | ||||||||||
Gilenya | Neuroscience | Relapsing multiple sclerosis | 1 497 | 26 | 1 279 | 17 | 2 776 | 12 | 21 | ||||||||||
Lucentis | Retina | Age-related macular degeneration | 2 060 | -2 | 2 060 | -16 | -2 | ||||||||||||
Tasigna | Oncology | Chronic myeloid leukemia | 661 | 22 | 971 | 12 | 1 632 | 7 | 16 | ||||||||||
Sandostatin | Oncology | Carcinoid tumors and Acromegaly | 823 | 10 | 807 | 5 | 1 630 | -1 | 7 | ||||||||||
Afinitor/Votubia | Oncology | Breast cancer / TSC | 892 | 11 | 715 | 9 | 1 607 | 2 | 10 | ||||||||||
Diovan/Co–Diovan | Established Medicines | Hypertension | 254 | -74 | 1 030 | -17 | 1 284 | -45 | -40 | ||||||||||
Galvus | Cardio-Metabolic | Diabetes | 1 140 | 8 | 1 140 | -7 | 8 | ||||||||||||
Exforge | Established Medicines | Hypertension | 67 | -76 | 980 | 1 | 1 047 | -25 | -15 | ||||||||||
Exjade | Oncology | Chronic iron overload | 365 | 19 | 552 | 3 | 917 | -1 | 8 | ||||||||||
Xolair1 | Respiratory | Asthma | 755 | 14 | 755 | -3 | 14 | ||||||||||||
Exelon/Exelon Patch | Neuroscience | Alzheimer's disease | 340 | -30 | 388 | -13 | 728 | -28 | -21 | ||||||||||
Neoral/Sandimmun(e) | Immunology and Dermatology | Transplantation | 47 | -15 | 523 | -5 | 570 | -17 | -6 | ||||||||||
Votrient | Oncology | Renal cell carcinoma | 287 | nm | 278 | nm | 565 | nm | nm | ||||||||||
Voltaren (excl. other divisions) | Established Medicines | Inflammation/pain | 558 | 0 | 558 | -12 | 0 | ||||||||||||
Tafinlar/Mekinist | Oncology | Melanoma | 267 | nm | 186 | nm | 453 | nm | nm | ||||||||||
Myfortic | Immunology and Dermatology | Transplantation | 109 | -27 | 332 | 0 | 441 | -19 | -8 | ||||||||||
Jakavi | Oncology | Myelofibrosis | 410 | 71 | 410 | 47 | 71 | ||||||||||||
Promacta/Revolade | Oncology | Immune thrombocytopenic purpura | 196 | nm | 206 | nm | 402 | nm | nm | ||||||||||
Ritalin/Focalin | Established Medicines | Attention deficit/ hyperactivity disorder | 226 | -31 | 139 | 1 | 365 | -26 | -20 | ||||||||||
Top 20 products total | 8 564 | 7 | 15 434 | 7 | 23 998 | -3 | 7 | ||||||||||||
Rest of portfolio | 1 715 | -2 | 4 732 | 4 | 6 447 | -9 | 2 | ||||||||||||
Total Division sales | 10 279 | 5 | 20 166 | 6 | 30 445 | -4 | 6 | ||||||||||||
|
|||||||||||||||||||
1 Net sales reflect Xolair sales for all indications (e.g. including Xolair SAA and Xolair CSU, which are managed by the Immunology and Dermatology).
|
|||||||||||||||||||
nm = not meaningful |
Q4 2015 USD m |
Q4 2014 USD m |
% change USD |
% change cc |
||||||
Oncology | |||||||||
Gleevec/Glivec | 1 219 | 1 237 | -1 | 4 | |||||
Tasigna | 432 | 428 | 1 | 8 | |||||
Subtotal Bcr-Abl franchise | 1 651 | 1 665 | -1 | 5 | |||||
Sandostatin | 413 | 416 | -1 | 7 | |||||
Afinitor/Votubia | 382 | 426 | -10 | -4 | |||||
Exjade | 248 | 243 | 2 | 9 | |||||
Votrient | 176 | 0 | nm | nm | |||||
Tafinlar/Mekinist | 147 | 0 | nm | nm | |||||
Jakavi | 119 | 84 | 42 | 59 | |||||
Revolade/Promacta | 133 | 0 | nm | nm | |||||
Femara | 70 | 98 | -29 | -21 | |||||
Zykadia | 24 | 12 | 100 | 104 | |||||
Other | 203 | 138 | 47 | 59 | |||||
Total Oncology | 3 566 | 3 082 | 16 | 23 | |||||
Neuroscience | |||||||||
Gilenya | 742 | 666 | 11 | 18 | |||||
Exelon/Exelon Patch | 135 | 240 | -44 | -37 | |||||
Comtan/Stalevo | 75 | 89 | -16 | -7 | |||||
Other | 31 | 59 | -47 | -44 | |||||
Total Neuroscience | 983 | 1 054 | -7 | 0 | |||||
Retina | |||||||||
Lucentis | 499 | 588 | -15 | -4 | |||||
Other | 12 | 13 | -8 | -8 | |||||
Total Retina | 511 | 601 | -15 | -4 | |||||
Immunology and Dermatology | |||||||||
Neoral/Sandimmun(e) | 144 | 164 | -12 | -3 | |||||
Myfortic | 115 | 131 | -12 | 0 | |||||
Zortress/Certican | 89 | 85 | 5 | 17 | |||||
Cosentyx | 121 | 0 | nm | nm | |||||
Ilaris | 63 | 54 | 17 | 25 | |||||
Other | 38 | 45 | -16 | -8 | |||||
Subtotal Immunology and Dermatology excluding Everolimus stent drug | 570 | 479 | 19 | 30 | |||||
Everolimus stent drug | 58 | 62 | -6 | -7 | |||||
Total Immunology and Dermatology | 628 | 541 | 16 | 26 | |||||
Respiratory | |||||||||
Ultibro Breezhaler | 76 | 51 | 49 | 68 | |||||
Onbrez Breezhaler/Arcapta Neohaler | 38 | 56 | -32 | -22 | |||||
Seebri Breezhaler | 37 | 42 | -12 | 1 | |||||
Subtotal COPD1 portfolio | 151 | 149 | 1 | 15 | |||||
Xolair2 | 197 | 200 | -2 | 12 | |||||
Other | 73 | 74 | -1 | 5 | |||||
Total Respiratory | 421 | 423 | 0 | 12 | |||||
Cardio-Metabolic | |||||||||
Galvus | 294 | 295 | 0 | 12 | |||||
Entresto | 5 | 0 | nm | nm | |||||
Total Cardio-Metabolic | 299 | 295 | 1 | 14 | |||||
Established Medicines | |||||||||
Diovan | 292 | 379 | -23 | -16 | |||||
Exforge | 249 | 298 | -16 | -7 | |||||
Voltaren (excluding other divisions) | 140 | 172 | -19 | -9 | |||||
Ritalin/Focalin | 80 | 128 | -38 | -32 | |||||
Other | 696 | 887 | -22 | -9 | |||||
Total Established Medicines | 1 457 | 1 864 | -22 | -12 | |||||
Total Division net sales | 7 865 | 7 860 | 0 | 9 | |||||
Of which Growth products3
|
3 658 | 2 969 | 23 | 34 | |||||
Of which rest of portfolio
|
4 207 | 4 891 | -14 | -6 | |||||
1 Chronic Obstructive Pulmonary Disease
|
|||||||||
2 Net sales reflect Xolair sales for all indications (e.g. including Xolair SAA and Xolair CSU, which are managed by the Immunology and Dermatology).
|
|||||||||
3 Growth products are an indicator of the rejuvenation of the portfolio, and comprise products launched in a key market (EU, US, Japan) in 2010 or later, or products with exclusivity until at least 2019 in key markets. They include the acquisition effect of the GSK oncology assets.
|
|||||||||
nm = not meaningful |
FY 2015 USD m |
FY 2014 USD m |
% change USD |
% change cc |
||||||
Oncology | |||||||||
Gleevec/Glivec | 4 658 | 4 746 | -2 | 5 | |||||
Tasigna | 1 632 | 1 529 | 7 | 16 | |||||
Subtotal Bcr-Abl franchise | 6 290 | 6 275 | 0 | 8 | |||||
Sandostatin | 1 630 | 1 650 | -1 | 7 | |||||
Afinitor/Votubia | 1 607 | 1 575 | 2 | 10 | |||||
Exjade | 917 | 926 | -1 | 8 | |||||
Votrient | 565 | 0 | nm | nm | |||||
Tafinlar/Mekinist | 453 | 0 | nm | nm | |||||
Jakavi | 410 | 279 | 47 | 71 | |||||
Revolade/Promacta | 402 | 0 | nm | nm | |||||
Femara | 304 | 380 | -20 | -11 | |||||
Zykadia | 79 | 31 | 155 | 162 | |||||
Other | 819 | 587 | 40 | 50 | |||||
Total Oncology | 13 476 | 11 703 | 15 | 24 | |||||
Neuroscience | |||||||||
Gilenya | 2 776 | 2 477 | 12 | 21 | |||||
Exelon/Exelon Patch | 728 | 1 009 | -28 | -21 | |||||
Comtan/Stalevo | 294 | 371 | -21 | -8 | |||||
Other | 141 | 243 | -42 | -35 | |||||
Total Neuroscience | 3 939 | 4 100 | -4 | 5 | |||||
Retina | |||||||||
Lucentis | 2 060 | 2 441 | -16 | -2 | |||||
Other | 50 | 63 | -21 | -12 | |||||
Total Retina | 2 110 | 2 504 | -16 | -3 | |||||
Immunology and Dermatology | |||||||||
Neoral/Sandimmun(e) | 570 | 684 | -17 | -6 | |||||
Myfortic | 441 | 543 | -19 | -8 | |||||
Zortress/Certican | 335 | 327 | 2 | 17 | |||||
Cosentyx | 261 | 0 | nm | nm | |||||
Ilaris | 236 | 199 | 19 | 30 | |||||
Other | 160 | 173 | -8 | 2 | |||||
Subtotal Immunology and Dermatology excluding Everolimus stent drug | 2 003 | 1 926 | 4 | 16 | |||||
Everolimus stent drug | 134 | 205 | -35 | -35 | |||||
Total Immunology and Dermatology | 2 137 | 2 131 | 0 | 11 | |||||
Respiratory | |||||||||
Ultibro Breezhaler | 260 | 118 | 120 | 157 | |||||
Onbrez Breezhaler/Arcapta Neohaler | 166 | 220 | -25 | -11 | |||||
Seebri Breezhaler | 150 | 146 | 3 | 21 | |||||
Subtotal COPD1 portfolio | 576 | 484 | 19 | 40 | |||||
Xolair2 | 755 | 777 | -3 | 14 | |||||
Other | 263 | 320 | -18 | -11 | |||||
Total Respiratory | 1 594 | 1 581 | 1 | 17 | |||||
Cardio-Metabolic | |||||||||
Galvus | 1 140 | 1 224 | -7 | 8 | |||||
Entresto | 21 | 0 | nm | nm | |||||
Other | 0 | 8 | nm | nm | |||||
Total Cardio-Metabolic | 1 161 | 1 232 | -6 | 9 | |||||
Established Medicines | |||||||||
Diovan | 1 284 | 2 345 | -45 | -40 | |||||
Exforge | 1 047 | 1 396 | -25 | -15 | |||||
Voltaren (excluding other divisions) | 558 | 632 | -12 | 0 | |||||
Ritalin/Focalin | 365 | 492 | -26 | -20 | |||||
Other | 2 774 | 3 675 | -25 | -14 | |||||
Total Established Medicines | 6 028 | 8 540 | -29 | -21 | |||||
Total Division net sales | 30 445 | 31 791 | -4 | 6 | |||||
Of which Growth products3
|
13 532 | 11 289 | 20 | 33 | |||||
Of which rest of portfolio
|
16 913 | 20 502 | -18 | -9 | |||||
1 Chronic Obstructive Pulmonary Disease
|
|||||||||
2 Net sales reflect Xolair sales for all indications (e.g. including Xolair SAA and Xolair CSU, which are managed by the Immunology and Dermatology).
|
|||||||||
3 Growth products are an indicator of the rejuvenation of the portfolio, and comprise products launched in a key market (EU, US, Japan) in 2010 or later, or products with exclusivity until at least 2019 in key markets. They include the acquisition effect of the GSK oncology assets.
|
|||||||||
nm = not meaningful |
Q4 2015 | Q4 2014 | % change | Q4 2015 | Q4 2014 | |||||||||
USD m | USD m | USD | cc | % of total | % of total | ||||||||
Pharmaceuticals | |||||||||||||
Europe
|
2 646 | 2 733 | -3 | 10 | 34 | 35 | |||||||
US
|
2 643 | 2 374 | 11 | 11 | 34 | 30 | |||||||
Asia/Africa/Australasia
|
1 932 | 1 880 | 3 | 9 | 25 | 24 | |||||||
Canada and Latin America
|
644 | 873 | -26 | -1 | 7 | 11 | |||||||
Total | 7 865 | 7 860 | 0 | 9 | 100 | 100 | |||||||
Of which in Established Markets
|
5 836 | 5 687 | 3 | 9 | 74 | 72 | |||||||
Of which in Emerging Growth Markets
|
2 029 | 2 173 | -7 | 9 | 26 | 28 | |||||||
Alcon | |||||||||||||
Europe
|
601 | 695 | -14 | 0 | 26 | 26 | |||||||
US
|
1 003 | 1 108 | -9 | -9 | 43 | 41 | |||||||
Asia/Africa/Australasia
|
517 | 610 | -15 | -9 | 22 | 23 | |||||||
Canada and Latin America
|
228 | 290 | -21 | 3 | 9 | 10 | |||||||
Total | 2 349 | 2 703 | -13 | -6 | 100 | 100 | |||||||
Of which in Established Markets
|
1 779 | 1 995 | -11 | -6 | 76 | 74 | |||||||
Of which in Emerging Growth Markets
|
570 | 708 | -19 | -4 | 24 | 26 | |||||||
Sandoz | |||||||||||||
Europe
|
987 | 1 111 | -11 | 3 | 43 | 44 | |||||||
US
|
900 | 935 | -4 | -3 | 39 | 37 | |||||||
Asia/Africa/Australasia
|
283 | 308 | -8 | 0 | 12 | 12 | |||||||
Canada and Latin America
|
136 | 158 | -14 | 6 | 6 | 7 | |||||||
Total | 2 306 | 2 512 | -8 | 0 | 100 | 100 | |||||||
Of which in Established Markets
|
1 782 | 1 877 | -5 | 1 | 77 | 75 | |||||||
Of which in Emerging Growth Markets
|
524 | 635 | -17 | -2 | 23 | 25 | |||||||
Continuing operations | |||||||||||||
Europe
|
4 234 | 4 539 | -7 | 7 | 34 | 35 | |||||||
US
|
4 546 | 4 417 | 3 | 3 | 36 | 34 | |||||||
Asia/Africa/Australasia
|
2 732 | 2 798 | -2 | 4 | 22 | 21 | |||||||
Canada and Latin America
|
1 008 | 1 321 | -24 | 1 | 8 | 10 | |||||||
Total continuing operations | 12 520 | 13 075 | -4 | 4 | 100 | 100 | |||||||
Of which in Established Markets
|
9 397 | 9 559 | -2 | 4 | 75 | 73 | |||||||
Of which in Emerging Growth Markets
|
3 123 | 3 516 | -11 | 4 | 25 | 27 | |||||||
Discontinued operations2 | |||||||||||||
Europe
|
663 | nm | nm | 43 | |||||||||
US
|
375 | nm | nm | 24 | |||||||||
Asia/Africa/Australasia
|
305 | nm | nm | 20 | |||||||||
Canada and Latin America
|
215 | nm | nm | 13 | |||||||||
Total discontinued operations | 1 558 | nm | nm | 100 | |||||||||
Of which in Established Markets
|
1 022 | nm | nm | 66 | |||||||||
Of which in Emerging Growth Markets
|
536 | nm | nm | 34 | |||||||||
1 Net sales from operations by location of third party customer. Emerging Growth Markets comprise all markets other than the Established Markets of the US, Canada, Western Europe, Japan, Australia and New Zealand.
|
|||||||||||||
2 Discontinued operations are defined on page 43.
|
|||||||||||||
nm = not meaningful
|
FY 2015 | FY 2014 | % change | FY 2015 | FY 2014 | |||||||||
USD m | USD m | USD | cc | % of total | % of total | ||||||||
Pharmaceuticals | |||||||||||||
Europe
|
10 139 | 11 245 | -10 | 7 | 33 | 35 | |||||||
US
|
10 279 | 9 772 | 5 | 5 | 34 | 31 | |||||||
Asia/Africa/Australasia
|
7 224 | 7 655 | -6 | 3 | 24 | 24 | |||||||
Canada and Latin America
|
2 803 | 3 119 | -10 | 10 | 9 | 10 | |||||||
Total | 30 445 | 31 791 | -4 | 6 | 100 | 100 | |||||||
Of which in Established Markets
|
22 615 | 23 653 | -4 | 5 | 74 | 74 | |||||||
Of which in Emerging Growth Markets
|
7 830 | 8 138 | -4 | 9 | 26 | 26 | |||||||
Alcon | |||||||||||||
Europe
|
2 408 | 2 872 | -16 | 1 | 25 | 27 | |||||||
US
|
4 275 | 4 349 | -2 | -2 | 44 | 40 | |||||||
Asia/Africa/Australasia
|
2 154 | 2 449 | -12 | -4 | 22 | 23 | |||||||
Canada and Latin America
|
975 | 1 157 | -16 | 3 | 9 | 10 | |||||||
Total | 9 812 | 10 827 | -9 | -1 | 100 | 100 | |||||||
Of which in Established Markets
|
7 423 | 8 049 | -8 | -1 | 76 | 74 | |||||||
Of which in Emerging Growth Markets
|
2 389 | 2 778 | -14 | 0 | 24 | 26 | |||||||
Sandoz | |||||||||||||
Europe
|
3 925 | 4 573 | -14 | 5 | 43 | 48 | |||||||
US
|
3 525 | 3 215 | 10 | 10 | 38 | 34 | |||||||
Asia/Africa/Australasia
|
1 150 | 1 168 | -2 | 7 | 13 | 12 | |||||||
Canada and Latin America
|
557 | 606 | -8 | 11 | 6 | 6 | |||||||
Total | 9 157 | 9 562 | -4 | 7 | 100 | 100 | |||||||
Of which in Established Markets
|
6 972 | 7 035 | -1 | 8 | 76 | 74 | |||||||
Of which in Emerging Growth Markets
|
2 185 | 2 527 | -14 | 5 | 24 | 26 | |||||||
Continuing operations | |||||||||||||
Europe
|
16 472 | 18 690 | -12 | 6 | 33 | 36 | |||||||
US
|
18 079 | 17 336 | 4 | 4 | 37 | 33 | |||||||
Asia/Africa/Australasia
|
10 528 | 11 272 | -7 | 2 | 21 | 22 | |||||||
Canada and Latin America
|
4 335 | 4 882 | -11 | 9 | 9 | 9 | |||||||
Total continuing operations | 49 414 | 52 180 | -5 | 5 | 100 | 100 | |||||||
Of which in Established Markets
|
37 010 | 38 737 | -4 | 4 | 75 | 74 | |||||||
Of which in Emerging Growth Markets
|
12 404 | 13 443 | -8 | 7 | 25 | 26 | |||||||
Discontinued operations2 | |||||||||||||
Europe
|
313 | 2 608 | nm | nm | 52 | 45 | |||||||
US
|
133 | 1 456 | nm | nm | 22 | 25 | |||||||
Asia/Africa/Australasia
|
86 | 1 082 | nm | nm | 14 | 19 | |||||||
Canada and Latin America
|
69 | 670 | nm | nm | 12 | 11 | |||||||
Total discontinued operations | 601 | 5 816 | nm | nm | 100 | 100 | |||||||
Of which in Established Markets
|
422 | 3 910 | nm | nm | 70 | 67 | |||||||
Of which in Emerging Growth Markets
|
179 | 1 906 | nm | nm | 30 | 33 | |||||||
1 Net sales from operations by location of third party customer. Emerging Growth Markets comprise all markets other than the Established Markets of the US, Canada, Western Europe, Japan, Australia and New Zealand.
|
|||||||||||||
2 Discontinued operations are defined on page 43.
|
|||||||||||||
nm = not meaningful
|
Average rates Q4 2015 USD |
Average rates Q4 2014 USD |
Period-end rates Dec 31, 2015 USD |
Period-end rates Dec 31, 2014 USD |
||||||
1 CHF | 1.010 | 1.037 | 1.011 | 1.010 | |||||
1 CNY | 0.156 | 0.163 | 0.154 | 0.161 | |||||
1 EUR | 1.095 | 1.249 | 1.093 | 1.215 | |||||
1 GBP | 1.517 | 1.583 | 1.483 | 1.556 | |||||
100 JPY | 0.824 | 0.875 | 0.831 | 0.836 | |||||
100 RUB | 1.516 | 2.125 | 1.362 | 1.722 | |||||
Average rates FY 2015 USD |
Average rates FY 2014 USD |
Period-end rates Dec 31, 2015 USD |
Period-end rates Dec 31, 2014 USD |
||||||
1 CHF | 1.040 | 1.094 | 1.011 | 1.010 | |||||
1 CNY | 0.159 | 0.162 | 0.154 | 0.161 | |||||
1 EUR | 1.110 | 1.329 | 1.093 | 1.215 | |||||
1 GBP | 1.529 | 1.648 | 1.483 | 1.556 | |||||
100 JPY | 0.826 | 0.947 | 0.831 | 0.836 | |||||
100 RUB | 1.649 | 2.649 | 1.362 | 1.722 | |||||
Q4 2015 USD m |
Q4 2014 USD m |
FY 2015 USD m |
FY 2014 USD m |
||||||
Share of estimated Roche reported results
|
122 | 191 | 650 | 813 | |||||
Prior-year adjustment
|
-157 | -56 | |||||||
Amortization of additional intangible assets recognized by Novartis on initial accounting for the equity interest
|
-37 | -38 | -150 | -158 | |||||
Net income effect from Roche Holding AG | 85 | 153 | 343 | 599 | |||||
Share of estimated GSK CH reported results
|
-14 | -17 | |||||||
Amortization of additional intangible assets recognized by Novartis on initial accounting for the equity interest
|
-62 | -62 | |||||||
Net income effect from GlaxoSmithKline Consumer Healthcare Holdings | -76 | -79 | |||||||
Gain on divestment of Idenix shares | 812 | ||||||||
LTS Lohmann Therapie-Systeme AG | 421 | 436 | |||||||
Income from other associated companies related to continuing operations | 1 | 6 | 2 | 71 | |||||
Income from associated companies related to continuing operations | 10 | 580 | 266 | 1 918 | |||||
|
Q4 2015 USD m |
Q4 2014 USD m |
FY 2015 USD m |
FY 2014 USD m |
||||||
Income from associated companies related to continuing operations | 10 | 580 | 266 | 1 918 | |||||
Share of estimated Roche core adjustments | 104 | 50 | 423 | 257 | |||||
Share of estimated GlaxoSmithKline Consumer Healthcare Holdings core adjustments | 129 | 292 | |||||||
Reversal of gain on Idenix shares | -812 | ||||||||
Reversal of gain on LTS Lohmann Therapie-Systeme AG shares | -421 | -421 | |||||||
Others | 1 | 1 | |||||||
Core income from associated companies related to continuing operations | 243 | 210 | 981 | 943 | |||||
|
1 Year Novartis Ag Basel Namen ... (PK) Chart |
1 Month Novartis Ag Basel Namen ... (PK) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions